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ABSTRACT 
A SYNTHETIC BIOLOGY APPROACH TO ENGINEERING 
NEW ANTICANCER AGENTS 
by 
 
Shane Robert Wesener 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Associate Professor Dr. Yi-Qiang Cheng 
 
 
Histone deacetylase (HDAC) inhibitors are becoming increasingly valuable 
therapeutic agents in treatment of several types of malignancies. FK228 is a depsipeptde 
anticancer compound produced by Chromobacterium violaceum no. 968 through a 
nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) hybrid assembly 
line. In the present study, reconstitution of the biosynthetic pathway responsible for the 
production of FK228 revealed cross-talk between modular PKS and fatty acid synthase. 
This pathway contains two PKS modules on the DepBC enzymes that lack a functional 
acyltransferase (AT) domain, and no apparent AT-encoding gene exists within the gene 
cluster or its vicinity. We reported through heterologous expression of the FK228 
biosynthetic pathway in E. coli cells, two essential genes, fabD1 and fabD2, both 
encoding a putative malonyl CoA acyltransferase component of the fatty acid synthase 
complex, are positively identified to be involved in FK228 biosynthesis. Either gene 
product appears sufficient to complement the “AT-less” PKS modules on DepBC for 
polyketide chain elongation. Concurrently a gene (sfp) encoding a putative Sfp-type 
phosphopantetheinyltransferase was identified to be necessary for FK228 biosynthesis as 
well. Importantly, engineered E. coli strains carrying variable genetic components 
produced significant levels of FK228 under both aerobic and anaerobic cultivation 
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conditions. Discovery of the trans complementation of modular PKSs by housekeeping 
ATs reveals natural product biosynthesis diversity. Moreover, demonstration of anaerobic 
production of FK228 by an engineered facultative bacterial strain validates our effort 
toward engineering of novel tumor-targeting bio-agents.  The second part of the 
dissertation focused on the engineering of cell penetrating peptides (CPPs) with 
anticancer activity.  A fusion protein combining the transmembrane activity of a bacterial 
CPP with a eukaryotic mitochondrial disrupting protein (MDP) was constructed to 
become a new CPP-MDP protein with anticancer activity.  A new E. coli BL21(DE3)-
based expression system that facilitates the secretion of CPP fusion proteins into the 
growth media for rapid and efficient protein purification was also created.  This protein 
secretion system utilizes induced L-form bacterial spheroplasts to generate a yield of 32 
mg/L of CPP-MDP directly from the media.  Construction of an L-form based E. coli 
BL21 (DE3) protein secretion system and a modular CPP expression system allows 
future rapid CPP-fusion protein production with new fusion protein partners to develop 
new CPP-based anticancer agents.   
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1.1 Targeting Cancer 
Cancer continues to be a major public health problem and the development of 
effective cancer treatments with no or few side effects remains one of the most difficult 
scientific challenges in medicine. Cancer occurs in many tissue types (such as breast 
cancer, skin cancer, or leukemia) and the effectiveness of conventional treatments 
(surgical removal, radiotherapy and chemotherapy) varies (1). Consequently, there have 
been intensive efforts to develop alternative cancer therapies including bone marrow 
transplantation, immunotherapy, gene therapy, hormone therapy, and inhibition of 
angiogenesis (formation of blood vessels) or specific protein targets (mostly kinases) in 
key signaling pathways, with mixed success (2).  Many current therapies using radiation, 
platinum and nucleic acid analogs have activity against cancer cells but are also toxic to 
normal tissue.  Furthermore, many cancer cell lines have developed resistance to one or 
all of these treatments, limiting their effectiveness (3).   Current goals in the development 
of new anticancer agents combine high activity toward cancer cells while limiting 
toxicity to preserve healthy tissue.  In order to overcome issues of toxicity and resistance, 
research has focused on developing new therapies that target specific cellular pathways in 
cancer cells such as apoptosis, cell cycle regulation, mitochondrial growth and repair, 
endoplasmic protein folding and transport and reactive oxygen species (ROS) repair.   
The trademark of cancer cells is the development of pro-cancer genetic and 
epigenetic changes that uncouple the regulatory controls of both cellular division and cell 
death.  These genetic mutational and transcriptional activities impart new survival 
advantages over normal tissue.  The aberrant cancer cells gain the ability to infinitely 
divide and out-compete surrounding cells for nutrients. Furthermore, the new genetic 
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influences lead to the rapid growth of tumors and the physiologic changes that preserve 
the abnormal cells.   
 
1.2 Epigenetics of Cancer 
Traditional cancer research focuses on genetic regulation and the respective 
mutations that lead to the various cancer phenotypes.  The field of epigenetics relates to 
the inherited genetic expression patterns associated with environmental adaptation (4).  
Both the genetic and epigenetic changes are important determinants of cancer 
development and progression, and epigenetic changes may preclude mutational changes 
leading to cancer. In comparison to inherited genetic changes, inherited epigenetic gene 
transcription levels are environmentally linked adaptations and are reversible 
chromosomal structure changes that exert significant control on chromosomal activation 
and gene regulation. Epigenetic chromosomal changes can favor genetic mutation, and 
enhance gene mutation effects by deactivating a chromosomal region related to the 
activation of oncogenes and tumor suppressor genes (5). Current epigenetic research 
therefore focuses on determining the effect of gene mutations or DNA sequence changes 
from epigenetic changes with regard to onset and progression of cancer. As with genetic 
mutations, epigenetic changes may alter more than one pathway leading to the 
development of a pro-cancerous state or cancer. In many cases, frequent epigenetic 
changes may create a cancer susceptible cell which is prone to develop genetic mutation 
leading to a cancerous state (4).  
The reversible chromosomal modifications are capable of converting a “malignant 
state” of a cell to a “normal state” either through intrinsic factors or with extrinsic factors 
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targeting epigenetic chromosomal modifications.  Two major epigenetic changes in the 
cell targeted to return a malignant cell to a normal gene expression state are DNA 
methylation and modifications of the histone tails including acetylation (4, 6) have been 
elucidated. It is hypothesized that both DNA methylation and histone acetylation result in 
similar changes in the control of regional chromosomal activation.  DNA methylation is 
controlled by DNA methyl transferases (DMT), while histone tail modifications are either 
methylated or acetylated.  The methyl regulation of the histone tails are coordinated by 
reversible histone methyl transferases (HMT) that adds or removes methyl groups from 
the N terminal histone tails.  Alternatively, the histone acetyl transferases (HAT) add 
acetyl groups onto lysine residues on histone tails and histone deacetylases (HDAC) 
catalyze removal of acetyl groups from lysine residues on histone tails. 
The major epigenetic changes associated with cancer are related to the regulatory 
activities of HAT and HDAC which usually determine chromosomal activity states.  
DNA exists in one of two structural states; euchromatin (open for transcription) or 
heterochromatin (closed for transcription). Increased euchromatin based transcription 
activity is related to HAT activity by increasing the acetylation of histone tail lysine 
residues, which decreases the affinity of DNA to histones, resulting in an open 
transcription state.  In contrast, HDAC activity removes acetyl groups from histone tails, 
increasing the affinity of DNA to histones causing an increase in chromatin compaction 
preventing transcription (4, 6) (Figure 1). The reversion of deactivated chromosomal 
regions is the focus of epigenetic therapy aiming to reactivate transcription of tumor 
suppressor genes and other genes that are related to a normal cell gene expression state 
(7). Two common epigenetic therapies currently on the market involve inhibitors of 
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DMTs and HDACs. The correlation between histone tail lysine acetylation and chromatin 
remodeling producing an open transcription state was demonstrated to be an effective 
epigenetic anticancer therapy where HDAC inhibition resulted in an increased open 
chromatin structure (6). The effectiveness of HDAC inhibition has led to the continued 
search and development of new compounds targeting the specific HDACs to elucidate the 
chromosomal remodeling pathways. 
 
Figure 1.  The methylation and acetylation epigenetic modifications of DNA and 
chromosomes regulate the gene transcriptional processes. Normally, the conversion of 
genetic information encoded in the DNA into gene products via transcription, requires the 
DNA to be in an "open" state where histone proteins (light blue) are modified by the 
addition of acetyl groups (green). Acetylation of the histones tails results in a relaxed 
chromatin configuration allowing the transcriptional machinery access to the DNA.  
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DNA methyltransferases (DNMTs), can add methyl groups (red) to the DNA at specific 
sequences of DNA causing the recruitment of methyl binding domain (MBD) protein 
complexes that includes repressor proteins, such as histone deacetylases (HDAC). The 
HDACs remove acetyl groups from histone proteins resulting in condensed chromatin 
that blocks the transcriptional machinery. Therefore, both DNMT and HDAC cause a 
reduction in gene transcription and may deactivate key tumor suppressor genes. New 
therapies targeting DNMTs and HDACs that inhibit these enzymes can return the 
chromatin to a relaxed state, allowing gene transcription.  Adapted from Moonat and 
Pandey, 2012 (8). 
 
 
1.3 Human HDAC Classes and Function 
The discovery of chromosomal inactivation associated with tumor suppressor 
gene silencing has identified HDACs as a potential target in epigenetic cancer therapy 
(9). The human HDAC superfamily is divided into classes I, II, III and IV based on 
structure, phylogeny and biological activity (10). Classes I, II and IV are termed 
“classical HDACs” containing zinc as a cofactor in the catalytic pocket. The classical 
HDACs reaction cleaves the amide bond between ε-amino group on lysine residues and 
the terminal acetyl group in the N-terminal tail. Class III HDACs are also called the 
sirtuins and contain nicotine adenine di-nucleotide (NAD)-dependent enzymes, including 
the silent information regulator (Sir)-2 family (11). Currently, only the classical HDAC 
family has been targeted for epigenetic therapy and many inhibitors of this family have 
progressed through clinical trials and on to the market as therapeutic agents (12, 13). 
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Currently, the human genome contains 18 HDACs belonging to the four superfamily 
classes. The Class I HDACs contains HDAC1, HDAC2, HDAC3 and HDAC8 and are 
localized only in the nucleus. While, Class II consists of HDAC4, HDAC5, HDAC6, 
HDAC7, HDAC9 and HDAC10 and are found in the cytoplasm but can also migrate to 
the nucleus. Class IV consists of the hybrid HDAC11, that shares similarity with both 
class I and class II HDACs. The remaining seven HDAC members are zinc-independent 
and NAD-dependent enzymes belonging to Class III HDACs.  
 Structural examination of Class I HDACs identified the catalytic mechanism 
associated with acetyl transferase activity and inhibition. The catalytic pocket responsible 
for hydrolysis of acetyl-lysine amide bond contains a Zn
2+
 ion. The ion is bound to two 
negatively charged aspartic acid residues and one histidine residue, leaving open two 
coordination sites for acetyl-lysine interactions from histone tails (14). The crystal 
structure of the HDAC8 catalytic pocket was shown to resemble a long tunnel largely 
composed of hydrophobic residues.  This hydrophobic tunnel was postulated to make 
contact with the lysine residues from histone tails and guide the terminal acetyl group to 
the catalytic core.  Also, the amino acids surrounding the entrance to the catalytic pocket 
of HDACs are responsible for surface recognition interactions critical to selectivity.  The 
structural information of the catalytic center and surrounding pocket provide important 
information related to the design of HDAC inhibitors (14, 15).      
 
1.4 Effects of HDAC Inhibition 
HDAC inhibition has been connected with broad epigenetic changes with various 
anticancer effects such as increase in genome wide gene expression, anti-angiogenesis, 
8 
 
 
 
cell cycle arrest, cellular differentiation, apoptosis and tumor regression (Figure 2) (16, 
4). The therapeutic action of HDACs inhibition leads to hyper-acetylation of histones 
which reduces the affinity of DNA to histones because of the neutralized positive charge 
on lysine residues. The euchromatin open structure is thought to increase the gene 
expression of tumor suppressor genes which is one of the various mechanisms suggested 
for anticancer effects stemming from HDAC inhibition (17). In particular, acetylation of 
histones has been shown to direct chromatin assembly, DNA recombination and repair 
(18). Also, inhibition of HDACs may affect both histone HDACs and non-histone 
substrates leading to similar results (16). While there is considerable difference in the 
mechanisms proposed for the anticancer effects, new evidence has shown HDAC 
inhibition increases the expression of pro-apoptosis signals suppressed in cancer cells 
(19).   Also, anticancer chromosomal changes are dependent on which HDACs they 
inhibit.  HDAC inhibitors may be termed as pan-HDAC inhibitors which inhibit all 
classical HDACs, or as isoform-selective inhibitors which inhibit only a certain class 
(20). There is evidence suggesting that pan-HDAC inhibitors affect multiple cellular 
pathways that are dependent on acetylation of histone tails and are not related to onset or 
progression of cancer. Events resulting from nonspecific HDAC inhibition may be 
circumvented with application of isoform-specific HDACi (17).   This evidence suggests 
isoform-specific HDAC inhibitors may provide critical insight into the regulation of 
epigenetic chromosomal changes and identifies the need for new HDAC inhibitors that 
limit broad changes in expression patterns. 
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Figure 2.  Pathway specificity and expression levels of class I and Class II HDACs lead 
to cancer phenotypes.  Decreased expression (red lines) of specific HDACs result in 
apoptosis, cell cycle arrest and growth inhibition.  In contrast, overexpression (green 
arrows) of specific HDACs increases proliferation, resistance to chemotherapy, cancer 
cell migration and angiogenesis.  FK228 has strong inhibitory action on class I HDAC 1 
and HDAC 2, reversing the HDAC specific cancer phenotypes. Adapted from Witt, O. et 
al. 2009 (21). 
 
1.5 Natural Product Biosynthesis by NRPS and PKS Systems 
The broad class of natural products (secondary metabolites) has shown to be a 
source of new HDAC inhibitors.  Natural products are considered to be non-essential to 
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the growth and development of bacteria but may provide selective survival advantages.  
In bacteria, secondary metabolites are often biosynthesized starting in middle to late 
logarithmic growth and into the stationary growth suggesting a physiological role in 
survival and maintenance. A majority of secondary metabolites are produced by three 
common biosynthetic systems; nonribosomal peptide synthetases (NRPS), polyketide 
synthases (PKS) and hybrid NRPS-PKS systems (22).  
Natural product biosynthesis from modular NRPS and PKS systems are produced 
in a similar “assembly line” fashion where NRPS and PKS multifunctional enzyme 
complexes are arranged in modules.  Typically, one substrate is added per module over 
the biosynthetic pathway with successive substrate addition until the product reaches full 
length.  The full length product is released by cyclization or hydrolysis. Structure of the 
biosynthetic product depends on the number of modules, the nature of substrates 
incorporated, accessory enzyme modification and the length of the final product. 
Modules are further defined by the individual protein domains with specific function 
integrated into the module. The unique nature of the protein domains within the module 
dictates the length, substrate specificity and reactions that occur at each module. A 
minimal NRPS module is composed of three distinct domains: adenylation (A) domain 
responsible for recognizing a specific amino acid substrate and adding it to the thiolation 
(T, also known as peptidyl carrier protein, PCP) domain that carries the substrate and 
moves it to the condensation (C) domain which is responsible for peptide bond formation 
between two successive substrates.  In contrast, a minimal PKS module consists of 
domains performing analogous functions to the NRPS module. It consists of an acyl 
transferase (AT) domain similar to A domain that determines acyl-CoA substrate 
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specificity, a thiolation (T, also known as acyl carrier protein, ACP) domain, and 
ketosynthase (KS) domain catalyzing the formation of a C-C bond through a claisen 
condensation reaction between successive substrates (22,23). The hybrid NRPS-PKS 
system combine modules from each biosynthetic system connected by thiolation domains 
that allow the addition of substrates by upstream KS or C domains.   
 A requirement for all PKS and NRPS biosynthetic pathways is the conversion of 
the apo-carrier proteins, ACP and PCP respectively, to the active holo form through the 
attachment of a 4’-phosphopantetheinate (Ppant) prosthetic group.  The transfer of the 
prosthetic group is catalyzed by a family of Mg
2+
 dependent 4’-phosphopantetheinyl 
transferases to a conserved serine within the consensus sequence GX(D/E/H)S motif on 
the ACP/PCP (24, 25).  The newly introduced thiol (-SH) group of the Ppant prosthetic 
group acts as a nucleophile for acylation by a substrate, which may be acyl-CoA or 
malonyl-CoA derivatives for the fatty acid and PKS, or aminoacyl-AMPs for the peptide 
and depsipeptide synthetases.  Therefore, the Ppant modification is a critical feature 
required by both NRPS and PKS modules that allows substrates to be tethered to a carrier 
protein (PCP or ACP) via a thioester bond.  
 The mechanism of chain elongation of both NRPS and PKS systems occurs in an 
assembly line fashion while substrates are bound as thioesters to the carrier protein.  In 
NRPS systems, the nucleophilic attack from the downstream aminoacyl-S-T on the 
upstream peptidyl-S-PCP results in chain elongation at that condensation domain between 
the modules. While in PKS systems, nucleophilic attack from the downstream thioester 
enolate on the upstream acyl-S-ACP leads to chain elongation by the upstream KS 
domain. Therefore in accordance with the colinearity rule, the number of modules in an 
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enzymatic assembly line of NRPS and PKS systems usually determines the chain length 
and the identity of the module A or AT domains define the substrates incorporated.  The 
identification of the substrates by A and AT domains dictates the structure of the 
secondary metabolite. Once the biosynthetic product reaches its full length, it can either 
be cyclized or hydrolyzed by a (type I) terminal thioesterase (TE) to release the product. 
In many secondary metabolite biosynthetic systems, tailoring reactions or post 
biosynthetic modifications like glycosylation, hydroxylation and oxidative cyclization 
occur after assembly line synthesis while in other systems the presence of embedded 
accessory domains may modify the final structure of the natural product (22, 23).  
Interestingly, PKS domains share an ancestral relationship to fatty acid 
biosynthetic domains and the PKS core domain structure can be modified to possess 
similar tailoring enzymes.  The fatty acid biosynthesis pathway consists of a core set of 
enzymes including a ketosynthase (KS), an acyl carrier protein (ACP), a keto-reductase 
(KR), a dehydrogenase (DH), enoyl reductase (ER), an acetyl-CoA acyl transferase (AT), 
and a malonyl-CoA:ACP acyl transferase (MAT).  In comparison to the minimal PKS 
domains consisting of a ketosynthase (KS), acyl carrier protein (ACP) and an acyl 
transferase (AT/MAT) for complete polyketide biosynthesis, the polyketide intermediates 
can also be modified by tailoring enzymes derived within the PKS gene cluster or from 
fatty acid biosynthesis, such as KRs, DHs, ERs, aromatases (AROs), and cyclases 
(CYCs) to yield a diverse array of natural products (26).  Additional modifications by 
other tailoring enzymes such as dimerases, P450 monooxygenases, methyltransferases, 
and glycosyltransferases can further elaborate the structure of the natural product.  New 
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modifications can contribute to significantly increase structure diversity and function of a 
molecule and has been shown to increase antibiotic activity (27). 
Whereas the NRPS and PKS multimodular and multienzyme assembly lines 
produce nonribosomal peptides and polyketides respectively, there are also examples of 
mixed NRPS-PKS systems in nature which biosynthesize hybrid NRPS-PKS natural 
products. The modular structure of NRPS and PKS biosynthetic systems and the 
compatible chemistry at the NRPS-PKS interface permits the biosynthesis of these hybrid 
natural products (22, 23).  
The dedicated function of biosynthetic pathways requires their streamlined 
genetic organization and this may reflect their coordinated regulation. Thus it is not 
surprising that genes required for the biosynthesis, tailoring and export of natural 
products are usually clustered (28, 29).    
 
1.6 Discovery and Bioactivities of the Natural Product FK228 as an HDAC Inhibitor 
The search for new cyclic depsipeptides with increased anticancer activities 
shows great promise for epigenetic anticancer treatment (17, 30, 31, 32). The FK228-
family of class specific HDAC inhibitors, consisting of FK228, thailandepsins and 
spiruchostatins, are natural products produced by Gram-negative bacteria. The function 
of cyclic depsipeptide within these bacteria is not clearly understood. The characteristic 
features of the FK228-family of compounds contain a bicyclic depsipeptide architecture, 
presence of an ester linkage (depsipeptide bond) and a disulfide bond to close the second 
ring structure (Figure 3).  
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Figure 3. Structures of FK228-family of  HDAC inhibitors. (A) FK228, (B) 
Spiruchostatin A (R=CH3) and Spiruchostatin B (R=CH2CH3), (C) Thailandepsin A 
(R=SCH3) and Thailandepsin B (R= CH2CH3). 
 
FK228 was discovered as a fermentation product of Chromobacterium violaceum 
no. 968, a Gram-negative cocco-bacillus opportunistic pathogen. Furumai discovered 
FK228 while screening for agents that could reverse malignant phenotype of Ha-ras cells 
to normal (33). In addition to significant anticancer activity against a variety of cell lines, 
FK228 also showed weak antibiotic activities (30, 33). FK228 exists in two forms. First, 
it acts as an inactive prodrug with its intact disulfide bond to diffuse across membranes. 
This is a key property that affects its bioavailability. Upon entry into the cell, intracellular 
reduction of the disulfide bond results in the formation of the active form with free 
sulfhydryl groups that can react with the active site zinc of class I HDACs  (30). HDAC 
inhibition ultimately results in a cascade of cellular changes that produce the anticancer 
effects and regression of cancer (34).  Furthermore, FK228 was granted FDA approval 
for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma 
A
. 
B
. 
 A
. 
C
. 
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(PTCL). This signifies the important role of cyclic depsipeptides in anticancer therapy 
and validates research towards developing and engineering structural analogs with 
improved therapeutic properties (34). 
   
1.7 Discovery and Function of Cell Penetrating Peptides 
 Cell-penetrating peptides (CPPs) are composed of relatively short basic peptides 
of 5 to 40 amino acids and possess the ability to cross the cell membrane through a 
number of mechanisms.  The membrane translocation process appears to be dependent on 
the cell type and the cargo that may be conjugated to the CPP (35).   Recent studies 
suggest that most CPPs enter eukaryotic cells through endocytosis uptake mechanisms, 
however small arginine-rich CPPs have been shown to cross the plasma membrane in an 
energy independent process (36).  CPPs can utilize both the clathrin-dependent and 
clathrin-independent endocytosis pathways to gain entrance into the cell and are able to 
escape from the endosomes to the cytoplasm.  Translocation from the endosome appears 
to be facilitated by endosome acidification allowing the CPP to cross the lipid bilayer 
(35, 37, 38).   Recently, YopM, a protein associated with Yersinia enterocolitica infection 
was shown to have cell translocation capabilities.  Normally, YopM and other pathogenic 
proteins are passed through the cell membrane via the type III secretion system.  This 
activity was attributed to two highly cationic amino acid regions within two alpha helices 
in the N-terminus that demonstrated the ability to translocate a fused protein cargo across 
the cellular membrane (39).   
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Table 1.  Common CPP sequences 
Names Sequences 
Penetratin RQIKIWFQNRRMKWKK 
Tat GRKKRRQRRRPPQ 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
MAP KLALKLALKALKAALKLA 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 
P1 MGLGLHLLVLAAALQGAWSQPKKKRKV 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 
Pep-1 KETWWETWWTEWSQPKKKRKV 
Arg9 RRRRRRRRR 
hCT LGTYTQDFNKFHTFPQTAIGVGAP 
 
 The membrane translocation activity of CPPs and CPP fusion proteins represents 
new engineering opportunities with vast therapeutic applications.  CPPs have been shown 
to deliver a variety of cargo including short inhibiting RNA, plasmids, proteins, 
liposomes, drugs and fluorescent markers, and represent a powerful strategy for drug 
delivery.  This strategy can be used to increase cancer cell activity of these anticancer 
agents by facilitating their delivery into tumor cells. Furthermore, the CPP 
transmembrane activity showed that drug resistant cancer cells could be reverted back to 
a drug sensitive phenotype by conjugating CPP with Taxol and other known anticancer 
drugs by increasing intracellular drug concentrations (40).  Also, CPPs conjugated with 
protein or protein domains can be used to specifically target pathways associated with a 
pro-cancer cell state or apoptosis pathways leading to cell death of cancer cells.  While 
cell targeting with most CPPs is ambiguous, recent studies identified CPPs with tumor 
targeting capabilities (41).  Finally, fluorescent labeled-CPP conjugates have been 
developed for surgical cancer therapy.  The fluorescent-CPP with an antibody specific for 
the cancer cells facilitates the endosomal escape of the conjugate preserving the 
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fluorescent signal within the cancer cell cytoplasm for easy surgical removal of only 
tumor tissue. Therefore, these unique peptides offer a variety of engineering options for 
the development of new anticancer agents and many other therapeutic applications. 
 
Figure 4.  Applications of CPP-cargo constructs.  Cell penetrating peptides are capable of  
transporting a variety of cargo across the cell membrane.  The variety of cargo makes 
CPPs a valuable shuttle targeting multiple cellular structures and pathways.  These 
characteristics have shown valuable in gene silencing, protein delivery, drug delivery and 
cellular imaging.  Adapted from Koren and Torchilin, 2012 (42). 
 
1.8 Targeting Mitochondrial Apoptosis Pathway for Cancer Therapy 
 The development of CPP anticancer peptides requires the identification of cellular 
targets capable of inducing cell death.  The translocation of CPPs to the cancer cell 
cytoplasm permits the targeting of the mitochondrial apoptotic pathway or downstream 
caspases associated with the death receptor pathway.   Normally cell death can be 
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induced by the binding of apoptosis-inducing ligands (such as FasL) to specific death 
receptors (such as FAS) located at the cell surface. The transmembrane receptor FAS, 
contains a cytoplasmic death domain where FADD (Fas-associated death domain) can 
bind in presence of FasL, and recruit pro-caspase 8.  This recruitment results in the 
activation of caspase 8 that initiates caspase 3 activation and subsequent activation of 
caspase activated DNase (CAD).  Caspase 3 cleaves I-CAD, the inhibitor of CAD 
releasing it to enter the nucleus and degrade DNA. Caspase 8 also cleaves Bid protein, 
resulting in a truncated Bid (tBid) (43).  Upon cleavage, tBid can dimerize with either 
Bax or Bad causing the release of cytochrome c from mitochondria (44). However, the 
mechanisms leading to mitochondrial membrane disruption and release of pro-apoptotic 
factors remain unclear. The disruption of the mitochondrial membrane leads to the 
release of cytochrome c, Smac/DIABLO (second mitochondrial-derived activator of 
caspase; Diablo: direct IAP-binding protein with low pI), AIF (apoptosis inducing factor) 
and procaspases.  The inhibitor Bcl2, prevents the release of cytochrome C and AIF in 
the cytoplasm. Once in the cytoplasm, cytochrome c binds to Apaf-1 (apoptosis protease 
activating factor) forming the apoptosome, which activates caspase 9 and downstream 
effector caspases. Smac/DIABLO binds to IAP (inhibitors of apoptosis) and prevent them 
from inhibition of the caspase 9 and caspase 3 activation (43). AIF has an indirect role in 
chromosome degradation as it activates endonuclease G, a DNase that moves from the 
mitochondria to the nucleus during apoptosis. Interestingly to note, the mtDNA is not 
fragmented during apoptosis. 
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Figure 5.  Death-receptor and mitochondrial apoptosis pathways.  Exploration of the two 
apoptosis pathways identified a number of intracellular targets to induce apoptosis with 
CPP constructs.  Adapted from Bayir and Kagan, 2008 (43). 
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CHAPTER 2 
 
RECONSTITUTION OF FK228 BIOSYNTHETIC PATHWAY REVEALING CROSS-
TALK BETWEEN MODULAR POLYKETIDE SYNTHASES AND FATTY ACID 
SYNTHASE 
 
 
 
 
 
 
 
 
 
Content of this chapter is a reformatted version of Wesener, S. W., Potharla, V. Y., and 
Y. Q. Cheng. 2011. Reconstitution of FK228 Biosynthetic Pathway Revealing Cross-
Talk between Modular Polyketide Synthases and Fatty Acid Synthase.  Appl Environ 
Microbiol  77: 1501-1507.
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2.1 Abstract 
 Functional cross-talk between fatty acid biosynthesis and secondary metabolism 
has been discovered in several cases in microorganisms, none of them however involves 
a modular biosynthetic enzyme. Previously we reported a hybrid modular nonribosomal 
peptide synthetase (NRPS)-polyketide synthase (PKS) pathway for the biosynthesis of 
FK228 anticancer depsipeptide in Chromobacterium violaceum no. 968. This pathway 
contains two PKS modules on the DepBC enzymes that lack a functional acyltransferase 
(AT) domain, and no apparent AT-encoding gene exists within the gene cluster or its 
vicinity. We report here that, through reconstitution of the FK228 biosynthetic pathway 
in E. coli cells, two essential genes, fabD1 and fabD2, both encoding a putative malonyl 
CoA acyltransferase component of the fatty acid synthase complex, are positively 
identified to be involved in FK228 biosynthesis. Either gene product appears sufficient to 
complement the “AT-less” PKS modules on DepBC for polyketide chain elongation. 
Concurrently a gene (sfp) encoding a putative Sfp-type phosphopantetheinyltransferase 
was identified to be necessary for FK228 biosynthesis as well. Most interestingly, 
engineered E. coli strains carrying variable genetic components produced significant 
levels of FK228 under both aerobic and anaerobic cultivation conditions. Discovery of 
the trans complementation of modular PKSs by housekeeping ATs reveals natural 
product biosynthesis diversity. Moreover, demonstration of anaerobic production of 
FK228 by an engineered facultative bacterial strain validates our effort toward 
engineering of novel tumor-targeting bio-agents. 
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2.2 Introduction 
 Polyketide synthases (PKSs) share many similarities with fatty acid synthases 
(FASs) and can be largely classified as type I, II and III, according to their architecture 
and mode of catalysis; yet many variants of PKSs exit in nature (5, 27, 29). Type I PKSs 
are multifunctional enzymes organized into modules, each of which harbors a set of 
distinct domains responsible for the catalysis of one cycle of polyketide chain elongation. 
A prototypical type I PKS elongation module contains minimally three integral domains 
– a ketosynthase (KS), an acyltransferase (AT) and an acyl carrier protein (ACP) – that 
together catalyze one round of polyketide chain elongation. Optional domains (such as 
ketoreductase [KR], dehydratase [DH], enoylreductase [ER]) are found between the AT 
and ACP domains, which carry out variable steps of reductive modifications on 
polyketide intermediate. Type II PKSs are multienzyme complexes that carry a single set 
of catalytic domains acting iteratively. Type III PKSs are chalcone synthase (CHS)-like 
enzymes that essentially are iteratively acting condensing enzymes. FASs, and type I and 
type II PKSs all use ACPs to tether acyl CoA substrates during fatty acid or polyketide 
biosynthesis, whereas type III PKSs directly condense acyl CoA substrates without 
carrier proteins. Prior to biosynthesis, apo form of ACPs must be activated to holo form 
by attaching a 4’-phosphopantetheinyl moiety from CoA onto a conserved serine residue; 
this posttranslational modification reaction is catalyzed by 
phosphopantetheinyltransferases (PPTases) that can be largely classified into two groups, 
AcpS-type and Sfp-type (12, 18, 22). 
 Integral AT domains in the prototypical type I PKSs were termed cognate ATs 
(8). A distinct variant of the type I PKSs contains no intact cognate ATs but a short 
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segment of remnant AT sequence in some or all modules. This subclass of type I PKSs 
was named the “AT-less” type I PKSs and the remnant AT segment the AT docking 
domain (7, 8, 31). The essential AT activities are provided in trans by discrete AT 
enzyme encoded by genes that are physically separated from the PKS genes, but 
nevertheless within the same gene cluster. 
 
 
  
Figure 6. Identification of missing genes necessary for FK228 biosynthesis in 
Chromobacterium violaceum no. 968. (A) Local genetic map of two candidate PPTase-
encoding genes, with the sfp gene product postulated to participate in 
phosphopantetheinylation of carrier proteins of the FK228 biosynthetic pathway. (B) 
Local genetic map of three candidate AT-encoding genes, with the fabD1 and fabD2 
gene products postulated to provide AT activities to complement the “AT-less” PKS 
modules on DepBC proteins for FK228 biosynthesis. (C) Scheme of two “AT-less” PKS 
modules on DepBC proteins that require a PPTase for carrier protein 
phosphopantetheinylation and a trans AT for polyketide chain elongation in FK228 
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biosynthesis. An inactive DH domain is drawn in light gray and labeled as DH
i
. KS, AT, 
ACP, DH, KR and PPTase are standard abbreviations of domain/enzyme names that have 
been described in the text. 
 
Our studies of the biosynthesis of FK228, a potent histone deacetylase inhibitor recently 
approved by FDA for the treatment of cutaneous T-cell lymphoma (CTCL) (1, 15), 
revealed that a 12-gene dep gene cluster encodes a hybrid modular NRPS-PKS pathway 
(9, 23), and that an FAD-dependent oxidoreductase is responsible for a critical disulfide 
bond formation in FK228 biosynthesis in Chromobacterium violaceum no. 968 (32). 
Nevertheless there are still several unanswered questions regarding the FK228 
biosynthetic pathway. In particular, the two PKS modules on DepBC enzymes do not 
contain any cognate AT domain but a remnant AT docking domain (Fig. 7C), and there is 
no AT-encoding gene anywhere in the defined dep gene cluster (9, 23). Where does the 
AT activity necessary for FK228 biosynthesis come from? In this work we report the 
identification of two essential genes, fabD1 and fabD2, both encoding a putative malonyl 
CoA acyltransferase (MCAT; also known as FabD, encoded by the fabD gene) 
component of the FAS II complex, that are positively involved in FK228 biosynthesis. 
Concurrently we identified a gene (sfp) encoding a putative Sfp-type PPTase necessary 
for FK228 biosynthesis as well. Furthermore, we show that, through reconstitution of the 
FK228 biosynthesis pathway, FK228 could be produced by recombinant E. coli strains 
under both aerobic and anaerobic cultivation conditions. Our studies revealed, for the first 
time, that modular PKSs recruit FabD components of the primary metabolism for the 
biosynthesis of a secondary metabolite. Discovery of the trans complementation of 
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modular PKSs by housekeeping ATs reveals natural product biosynthesis diversity. 
Moreover, demonstration of anaerobic production of FK228 by an engineered facultative 
bacterial strain validates our effort toward engineering of novel tumor-targeting bio-
agents (6). 
 
 
 
2.3 Materials and Methods 
 
2.3.1 Bacterial strains, plasmids, culture conditions, and general molecular biological 
manipulations.  
 The bacterial strains and plasmids used in this study are listed in Table 1. Culture 
conditions and general molecular biological manipulations were performed as described 
(9, 32), or according to standard protocols (25). 
 
2.3.2 Rapid genome sequencing and gene identification.  
 
 Genomic DNA of the wild type C. violaceum no. 968 strain was prepared from an 
overnight culture with an UltraClean Microbial DNA Isolation kit (MO BIO Labs, 
Carlsbad, CA), and was submitted for shotgun single-end and paired-end shotgun 
sequencing on a G20 FLX platform (454 Life Science, Branford, CT) at the Research 
Technology Support Facility of Michigan State University (East Lansing, MI). de novo 
assembly of sequence reads by instrument software was performed and resulted in a 
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quality draft genome sequence. Candidate genes were identified by using known protein 
sequences as bait to search the draft genome sequence of C. violaceum by Blastx 
algorithm (3). 
2.3.3 General strategies for targeted gene deletion in C. violaceum no. 968.  
 A multiplex PCR method, as described elsewhere (10, 23, 32), was used for all 
intended gene deletion experiments. This method utilized a broad host-range Flp-FRT 
recombination system for site-specific gene replacement/deletion and subsequent marker 
removal (10, 16). Primers used for making gene deletion constructs and for detection of 
genotypes are listed in Table 2. 
 
2.3.3 Reconstitution of FK228 biosynthetic gene cluster in engineered E. coli strains.  
 To probe whether individual candidate AT-encoding genes or PPTase-encoding 
genes are involved in FK228 biosynthesis, a three-plasmid system was utilized for gene 
cluster reconstitution and FK228 biosynthesis in bacterial strains derived from E. coli 
BL21(DE3) (Fig. 7A). First, all candidate genes were amplified by high fidelity PCR 
from the genomic DNA of C. violaceum with primer sets carrying designed restriction 
sites. Second, two candidate PPTase-encoding gene amplicons were double-digested with 
BamHI/HindIII and individually cloned into the first multiple cloning site (MCS) of 
pCDFDuet-1 (Novagen, Madison, WI) to create two intermediate constructs, pCDFDuet-
1-acpS and pCDFDuet-1-sfp. Third, two candidate AT-encoding gene amplicons were 
double-digested with NdeI/KpnI and individually cloned into the second multiple cloning 
site of pCDFDuet-1 to generate pCDFDuet-1-fabD1 and pCDFDuet-1-fabD2, or into the 
two previously made intermediate constructs to create a combination of 4 final 
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constructs, pCDFDuet-1-acpS-fabD1, pCDFDuet-1-acpS-fabD2, pCDFDuet-1-sfp-
fabD1, pCDFDuet-1-sfp-fabD2 (Table 1). Finally, the Cosmid 18, which carries the 
original incomplete FK228 biosynthetic gene cluster that lacks any AT-encoding gene or 
PPTase-encoding gene (9), and pBMTL-3-depR, which was created to complement a 
depR-deletion mutant of C. violaceum (23), were used in combination with the above 
expression constructs for the transformation of E. coli BL21(DE3) cells to create a series 
of bacterial strains (Table 2). Kanamycin at 25 µg/ml, chloramphenicol at 25 µg/ml, and 
streptomycin at 25 µg/ml were used individually or in combination for selection and 
maintenance of respective E. coli strains. 
2.3.4 Bacterial fermentation and quantification of FK228 production by liquid 
chromatography-mass spectrometry (LC-MS).  
 Wild type C. violaceum strain and recombinant E. coli strains were fermented 
aerobically for 4 days at 30ºC under constant agitation (200 rpm) in 50 ml of LB media 
supplemented with 1% (w/v) Diaion HP-20 resin (Sigma-Aldrich, St. Louis, MO) and 
appropriate antibiotics where necessary. Gene expression was induced with 0.5% (w/v) 
lactose and 0.1 mM IPTG when bacterial culture reached an OD600 of 0.4. Strict 
anaerobic fermentation of bacterial strains was carried out similarly for 5 days at room 
temperature in a Coy anaerobic chamber (Grass Lake, MI) with occasional manual 
agitation, except for that 0.05% (w/v) thioglycolate was added to the media to capture 
any oxidative species generated during fermentation. Extraction of metabolites, and 
detection and quantification of FK228 by LC-MS were performed as described (23). 
 
2.3.5 RNA extraction and reverse transcription (RT)-PCR.  
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 Recombinant E. coli BL21(DE3) strains were grown in LB media supplemented 
with appropriate antibiotics at 30ºC under constant agitation (200 rpm) to an OD600 of 
0.4. Five ml of each pre-induction sample was collected and the remaining cultures were 
induced with 0.5% (v/v) lactose and 0.1 mM IPTG. Aliquots of sample were collected at 
60 min and again at 120 min post induction. Preservation of sample aliquots, extraction 
of total RNA, and RT-PCR experiments were performed as described (23). Primers used 
for detection of individual gene expression are listed in Table 4. 
 
 
 
2.3.6 Nucleotide sequence accession numbers.  
 The nucleotide sequences of C. violaceum no. 968 genes reported in this paper 
have been deposited in the GenBank database under accession numbers HM449690 for 
16S rRNA gene, HM449691 for fabD1, HM449692 for fabD2, HM449693 for AT3, 
HM449694 for acpS, and HM449695 for sfp, respectively. 
 
2.4.1 Results 
 
2.4.2 Draft genome sequencing of Chromobacterium violaceum no. 968.  
 Shotgun sequencing of C. violaceum genomic DNA on a GS20 FLX Sequencer 
generated a total of 163,954,650 input bases, which were assembled into 122 contigs; 
among them 82 are large contigs (>500 nt) with an average contig size of 59,514 bps. 
Those contigs were further aligned into 15 scaffolds with a total length of 4,909,141 bps. 
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The sequence coverage for this draft bacterial genome was thus calculated at 33.4 folds, 
which exceeded the desired 30-fold oversampling of raw sequence for the 454 
pyrosequencing and de novo assembly technology platform (13). Compared to the 
published 4.75-Mb complete genome of a type strain of C. violaceum ATCC 12472 with 
a (G + C) content of 64.8% (11), the 4.91-Mb draft genome sequence of C. violaceum no. 
968 with an overall (G + C) content of 61.9% obtained in this study appears to be near 
complete. The quality of this draft genome sequence was assessed by the following 
analyses. First, a comparison of the 16S rDNA sequences of two C. violaceum strains 
revealed an overall 96% identity without a single gap (Fig. 9), indicating a high quality of 
the draft genome sequence and a taxonomical relatedness of the two strains. Second, a 
homology search by Blastn algorithm of the draft genome sequence using our previously 
published FK228 biosynthetic gene cluster sequence (GenBank no. EF210776) (9) as bait 
identified two contigs that carry the gene cluster with a 100% sequence identify and with 
a 1298-bp sequence gap (data not shown). This gap was artificially created due to two 
highly homologous regions within the gene cluster that were assembled into a single copy 
of sequence. 
 
2.4.3 Identification and initial characterization of candidate genes.  
 Sequences of three bait proteins, FabD of E. coli K-12 (GenBank no. 
AAC74176), FabD of C. violaceum ATCC 12472 (GenBank no. NP_903085) and LnmG 
of Streptomyces atroolivaceus S-140 (GenBank no. AAN85520), were used to search the 
draft genome sequence and identified three candidate genes, fabD1, fabD2 and AT3, that 
encode putative AT enzymes (FabD, MCAT or AT) (Table 3; Fig. 7B). Based on 
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bioinformatic analysis, the fabD1 gene lies within an apparent FAS II gene cluster that 
also includes fabH, fabG, acp and fabF, whereas fabD2 is a standalone gene whose 
function cannot be predicted a priori. The AT3 gene lies within a putative gene cluster 
that may be involved in cell-surface O-antigen biosynthesis. 
 Similarly, sequences of five bait proteins, AcpS of E. coli K-12 (GenBank no. 
P24224), Sfp of Bacillus subtilis (GenBank no. P39135), AcpS of C. violaceum ATCC 
12472 (GenBank no. NP_901742), EntD of C. violaceum ATCC 12472 (GenBank no. 
NP_902320) and PcpS of Pseudomonas aeruginosa PAO1 (GenBank no. AAG04554), 
were used to search the draft genome sequence and identified two candidate genes, acpS 
and sfp, that encode putative PPTase enzymes (AcpS; Sfp) (Table 3; Fig. 7A). The acpS 
gene appears to be a standalone gene likely involved in primary metabolite (e.g. fatty 
acid) biosynthesis. The sfp gene is located at the end of an apparent NRPS gene cluster, 
therefore it is likely involved in secondary metabolite (e.g. nonribosomal peptide or 
hybrid molecule) biosynthesis. 
 Individual candidate genes were subjected to targeted gene deletion by a well-
established multiplex PCR procedure to probe whether they play any roles in FK228 
biosynthesis. Only AT3 was successfully mutated and the mutant strain did not show any 
notable difference from the wild type strain (data not shown), suggesting that AT3 is 
disposable and is independent of FK228 biosynthesis. Thus AT3 was not further tested. In 
contrast, four other candidate genes, fabD1, fabD2, acpS and sfp, could not be mutated 
despite numerous attempts, indicating that they are all essential to the bacterial 
physiology and survival. They were then subjected to tests by a different strategy 
described below. 
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2.4.4 Reconstitution of the FK228 biosynthetic pathway in E. coli.  
 A series of recombinant E. coli strains were created herein (Table 2; Fig. 7A) and 
the relative levels of FK228 production by these strains were examined by LC-MS (Fig. 
8; Table 5 and Fig. 10). When Cosmid 18, the originally identified large construct that 
carries the dep gene cluster which definitely lacks an AT-encoding gene and a PPTase-
encoding gene (9), was introduced into E. coli BL21(DE3) cells, the recombinant strain 
SW01 failed to produce FK228. When a newly defined pathway regulatory gene, depR 
(23), was introduced into SW01 via a broad-host range construct pBMTL-3-depR, the 
resulting strain SW02 still did not produce any detectable level of FK228. When the 
candidate sfp gene was introduced into SW02 via a compatible construct pCDFDuet-1-
sfp, the resulting strain SW03 produced a moderate level of FK228. When either the 
candidate fabD1 or fabD2 gene was added in tandem with sfp on pCDFDuet-1-sfp-fabD1 
or pCDFDuet-1-sfp-fabD2 construct, the resulting strains of SW07 and SW08 produced 
significant levels of FK228. All other strains that received a single candidate gene of 
either acpS (strain SW04), fabD1 (strain SW05) or fabD2 (strain SW06), or two genes 
with acpS in tandem with either fabD1 (strain SW9) or fabD2 (strain SW10) did not 
show production of detectable level of FK228. Those observations led to the following 
conclusions: (1) the sfp gene but not the acpS gene is capable of converting all ACPs (and 
presumably peptidyl carrier proteins – PCPs) in the FK228 biosynthetic pathway from 
their inactive apo form to their active holo form; (2) indigenous E. coli AcpS cannot 
promiscuously act on those heterologous carrier proteins from a secondary metabolic 
pathway; (3) either gene product of the essential fabD1 or fabD2 gene of C. violaceum 
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no. 968 is able to complement the “AT-less” PKS modules on DepBC for polyketide 
chain extension; (4) even E. coli FabD (in the background in case of strain SW03) is able 
to provide the necessary AT activities for FK228 biosynthesis albeit at a lower rate; and 
(5) at this point we believe that genes necessary for FK228 biosynthesis have all been 
identified. 
 
2.4.5 RT-PCR verification of gene expression.  
 To verify whether key biosynthetic and regulatory genes for FK228 biosynthesis 
were adequately expressed in the SW07 recombinant strain under normal aerobic 
conditions, aliquots of bacterial culture were collected at three time points, total RNA 
samples were prepared and subjected to semi-quantitative RT-PCR analysis (Fig. 7B). 
Prior to chemical induction, all examined genes including two representative structural 
genes (depA and depJ) but excluding the 16S rDNA control were not expressed. This 
suggests that the depR gene in its native position on Cosmid 18 is not functioning in E. 
coli cells, likely due to a lack of proper external or internal stimulus, or signal 
transduction pathway, or other regulatory components; expression of the dep gene cluster 
carried by Cosmid 18 in E. coli cells requires an ectopic copy of depR driven by lactose-
inducible promoter on a pBMTL-3 vector. Upon induction by lactose and IPTG for the  
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Figure 7. Reconstitution of FK228 biosynthesis in E. coli cells. (A) Scheme of a three-
plasmid approach for reconstitution of FK228 biosynthetic pathway in E. coli 
BL21(DE3) cells. Only one cell containing one copy of each plasmid is drawn into 
picture for simplicity. A series of engineered strains were generated with different 
combinations of plasmids or different genes on plasmids (Table 2). (B) Examination of 
gene expression by semi-quantitative RT-PCR in engineered strain SW07 cultivated 
under aerobic conditions. 16S rDNA was amplified as an internal control. 
 
 
 
expression of depR from pBMTL-3-depR and for the expression of sfp and fabD1 from 
pCDFDuet-1-sfp-fabD1, those genes and two representative structural genes (depA and 
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depJ) were found to have expressed at 60 min post induction; and the gene expression 
reached higher levels at 120 min post induction.  
 
2.4.6 Production of FK228 under anaerobic fermentation conditions.  
 As a pilot study toward engineering of novel tumor-targeting bacterial agents that 
may effectively infiltrate, multiply and continuously produce an anticancer drug inside 
the hypoxic core of solid tumors (6), we examined whether the engineered SW07 strain 
may produce FK228 under anaerobic fermentation conditions. To our delight the SW07 
strain produced c.a.14.1% as much FK228 as did by the wild type C. violaceum strain or 
15.3% by the SW07 strain itself under aerobic conditions (Fig. 8; Table 5 and Fig. 10); 
this relative level of FK228 production was translated into 0.40 mg/L of actual yield or 
c.a. 741 nM concentration when normalized by FK228 standard. As a control, the wild 
type C. violaceum strain was also found to have produced a lower level of FK228 under 
anaerobic conditions. This Gram-negative bacterial species appeared to be able to survive 
and grow slightly during the first 24 hr under the strict anaerobic conditions tested. 
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Figure 8. Levels of FK228 produced by recombinant E. coli strains relative to the wild 
type strain of Chromobacterium violaceum no. 968 cultivated under aerobic conditions 
unless indicated by * for under anaerobic conditions. Data are mean values of duplicate 
experiments with error bars indicating standard deviation. Detailed strain information and 
FK228 levels are provided in Table 2 and Table 5. 
 
2.5.1 Discussion 
 Organizational and functional variation of PKSs leads to diverse structure of 
polyketide natural products (5, 27). The modular “AT-less” PKSs represent a severe 
deviation from the canonical type I PKSs (7, 8) and this phenomenon appears to be a 
transition state of complex enzyme evolution from FAS II to type II PKSs (28). 
Nevertheless in most “AT-less” PKS pathways the AT activities required for polyketide 
chain elongation are often encoded by discrete genes within the respective biosynthetic 
gene clusters. In the present work, for the first time, we uncovered an extreme case of 
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“AT-less” PKS system where the AT activity is encoded by fabDs, the essential bacterial 
genes involved in fatty acid biosynthesis. 
 As more and more modular “AT-less” PKSs are identified (7), it was not so 
surprising to find that the two PKS modules on DepBC do not contain an intact cognate 
AT domain but remnant of AT-docking segment (Fig. 7C). However a failure to identify 
any AT-encoding gene within or in the vicinity of the defined dep gene cluster was 
intriguing (9, 23). To address the mystery about where the necessary AT activities would 
come from, the genome of C. violaceum no. 968 was decoded by a rapid genome 
sequencing platform, revealing three candidate genes that may encode the AT activities 
for FK228 biosynthesis. However, attempts to identify the exact AT-encoding gene by a 
direct gene deletion approach was not successful, because two candidate genes (fabD1 
and fabD2) could not be mutated due to their apparent essential roles in bacterial 
viability. A third gene (AT3) could be mutated but the mutant did not show any obvious 
sign of physiological defect or decrease in FK228 production. 
 We then engineered a series of recombinant E. coli strains that harbor one to three 
compatible vectors that carry either the previously reported incomplete dep gene cluster 
or candidate genes identified in this work with three objectives in mind (Fig. 7A). First, 
we hoped to identify the missing AT-encoding gene and PPTase-encoding gene 
necessary for FK228 biosynthesis. Second, we hoped to reconstitute a functional FK228 
biosynthetic pathway in a heterologous host such as E. coli cells. Third, we hoped to 
demonstrate that FK228 could be produced by a recombinant E. coli strain under both 
aerobic conditions and particularly anaerobic conditions as a pilot experiment for genetic 
engineering of novel cancer-targeting bio-agents (6). 
43 
 
 
 
 Three engineered E. coli strains, SW03, SW07 and SW08, were subsequently 
found to produce variable amounts of FK228 under normal (aerobic) fermentation 
conditions. In addition to the Cosmid 18 and the depR gene on a vector, all these three 
strains received the sfp gene; while other E. coli strains, regardless of having the acpS 
gene or not, did not produce FK228. It was thus clear that the AcpS-type PPTase from 
either E. coli host or from C. violaceum cannot activate the carrier proteins from the 
FK228 biosynthetic pathway. Therefore it was concluded that the sfp gene, which was 
predicted to encode a broad substrate-range Sfp-type PPTase, is involved in FK228 
biosynthesis. This PPTase should have other essential function as well, otherwise the sfp 
gene could have been mutated in the first place. In addition, two of the three strains, 
SW07 and SW08, which also received either fabD1 or fabD2 gene of C. violaceum, 
produced much higher levels of FK228 than did by SW03. Those observations suggested 
that either fabD1 or fabD2 of C. violaceum is involved in FK228 and their involvement is 
interchangeable; it is also possible that both genes are redundantly involved in FK228 
biosynthesis. Surprisingly, the indigenous fabD of E. coli appeared to function as well for 
FK228 biosynthesis in the SW03 strain which received the sfp gene but not fabD1 or 
fabD2.  
 Sequence alignment of the C. violaceum FabD1 and FabD2, and E . coli FabD 
shows that FabD1 and FabD share a much higher amino acid sequence identity than other 
two sets of comparison (Fig. 11), suggesting that FabD1 is very likely the housekeeping 
FAS II component for bacterial fatty acid biosynthesis. The role of FabD2 is less certain. 
Besides a positive role in FK228 biosynthesis, FabD2 should have other essential 
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functions; otherwise the fabD2 gene could have been mutated in early experimental 
attempts. 
 Now it is proven that an MCAT component of FAS II is recruited by modular 
type I PKS modules on DepBC for FK228 biosynthesis, which establishes a unique 
functional cross-talk between bacterial primary metabolism and secondary metabolism, 
and adds new evidence to the phenomenon of complex enzyme evolution from FAS II to 
type II PKSs (28). Previously two type II PKS systems responsible for the biosynthesis of 
actinorhodin (24) or tetracenomycin (4, 14, 30) were found to recruit FabD of FAS II. 
Additional variants of cross-talk between bacterial primary metabolism and secondary 
metabolism have also been reported. For example, in the biosynthesis of quinoxaline 
antibiotics in two Streptomyces strains, an ACP from the primary FAS II is recruited by a 
standalone condensation domain of type II NRPS to form an initiation module of the 
biosynthetic pathway (26). Furthermore, cross-talk between a type I FAS (FAS I) for 
primary metabolism and a secondary FAS I for HC-toxin biosynthesis had also be 
postulated in the fungal species Cochliobolus carbonum where only one gene encoding 
the -subunit of FAS I was found in the secondary metabolic gene cluster, while the -
subunit of FAS I necessary for HC-toxin biosynthesis might be recruited from the 
primary FAS I (2). Recently an opposite example was reported in the apicidin 
biosynthetic pathway in Fusarium semitectum where a gene encoding the -subunit of 
FAS I is present in the apicidin biosynthetic gene cluster while the -subunit of FAS I 
necessary for apicidin biosynthesis is speculated to be recruited from the primary FAS I 
(17). 
 Lastly, the ability by which the engineered SW07 strain produced 0.4 mg/L of 
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actual yield or c.a. 741 nM concentration of FK228 under strict anaerobic conditions is 
worth highlighting. This accomplishment represents an important milestone toward the 
goal of engineering of tumor-targeting bio-agents (6). The next step will be undertaken to 
introduce the FK228 biosynthetic capacity into one or more selected nonpathogenic 
anaerobic bacterial species, such as Bifidobacterium longum or Clostridium oncolyticum 
(21, 33), so that when the engineered bacteria infiltrate and multiply inside the necrotic 
region of solid tumors, FK228 will be produced in situ. Because FK228 is a potent 
histone deacetylase inhibitor and a new anticancer drug effective in the lower nM range 
(19, 34), the synergistic efforts of bacterial oncolysis of tumor tissue and the anticancer 
activity of FK228 could potentially be clinically effective against many types of cancer. 
 
4. 6. Supplementary Figures 
 
 
Cv_No968_16S_rDNA          1 AACTGAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTA 50 
Cv_ATCC12472_16S_rDNA      1 AACTGAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTA 50 
                             ************************************************** 
 
Cv_No968_16S_rDNA         51 CACATGCAAGTCGAACGGTAACAGGGTGCTTGCACCGCTGACGAGTGGCG 100 
Cv_ATCC12472_16S_rDNA     51 CACATGCAAGTCGAACGGTAACAGGGTGCTTGCACCGCTGACGAGTGGCG 100 
                             ************************************************** 
 
Cv_No968_16S_rDNA        101 AACGGGTGAGTAATGCATCGGAATGTACCGTGTAATGGGGGATAGCTCGG 150 
Cv_ATCC12472_16S_rDNA    101 AACGGGTGAGTAATGCGTCGGAATGTACCGTGTAATGGGGGATAGCTCGG 150 
                             **************** ********************************* 
 
Cv_No968_16S_rDNA        151 CGAAAGCCGGATTAATACCGCATACGCCCTGAGGGGGAAAGTGGGGGACC 200 
Cv_ATCC12472_16S_rDNA    151 CGAAAGCCGGATTAATACCGCATACGCCCTGAGGGGGAAAGCGGGGGATC 200 
                             ***************************************** ****** * 
 
Cv_No968_16S_rDNA        201 GTAAGGCCTCACGTTATACGAGCAGCCGATGTCTGATTAGCTAGTTGGTG 250 
Cv_ATCC12472_16S_rDNA    201 GAAAGACCTCGCGTTATACGAGCAGCCGACGTCTGATTAGCTAGTTGGTG 250 
                             * *** **** ****************** ******************** 
 
Cv_No968_16S_rDNA        251 GGGTAAAGGCTCACCAAGGCTTCGATCAGTAGCGGGTCTGAGAGGATGAT 300 
Cv_ATCC12472_16S_rDNA    251 AGGTAAGAGCTCACCAAGGCGACGATCAGTAGCGGGTCTGAGAGGATGAT 300 
                              *****  ************  **************************** 
 
Cv_No968_16S_rDNA        301 CCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAG 350 
Cv_ATCC12472_16S_rDNA    301 CCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAG 350 
                             ************************************************** 
 
Cv_No968_16S_rDNA        351 TGGGGAATTTTGGACAATGGGCGCAAGCCTGATCCAGCCATGCCGCGTGT 400 
Cv_ATCC12472_16S_rDNA    351 TGGGGAATTTTGGACAATGGGGGCAACCCTGATCCAGCCATGCCGCGTGT 400 
                             ********************* **** *********************** 
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Cv_No968_16S_rDNA        401 CTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCCGGGAGCAAATCCC 450 
Cv_ATCC12472_16S_rDNA    401 CTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCAGGGAGGAAATCCC 450 
                             ************************************ ***** ******* 
 
Cv_No968_16S_rDNA        451 AGTGGTTAATACCTACTGGGGCTGAGAGTACCGGAAGAATAAGCACCGGC 500 
Cv_ATCC12472_16S_rDNA    451 GCTGGTTAATACCCGGCGGGGATGACAGTACCTGAAGAATAAGCACCGGC 500 
                               ***********    **** *** ****** ***************** 
 
Cv_No968_16S_rDNA        501 TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTAATCG 550 
Cv_ATCC12472_16S_rDNA    501 TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTAATCG 550 
                             ************************************** *********** 
 
Cv_No968_16S_rDNA        551 GAATTACTGGGCGTAAAGCGTGCGCAGGCGGTTGTGCAAGTCTGATGTGA 600 
Cv_ATCC12472_16S_rDNA    551 GAATTACTGGGCGTAAAGCGTGCGCAGGCGGTTGTGCAAGTCTGATGTGA 600 
                             ************************************************** 
 
Cv_No968_16S_rDNA        601 AAGCCCCGGGCTTAACCTGGGAACGGCATTGGAGACTGCACGACTAGAGT 650 
Cv_ATCC12472_16S_rDNA    601 AAGCCCCGGGCTTAACCTGGGAACGGCATTGGAGACTGCACAGCTAGAGT 650 
                             *****************************************  ******* 
 
Cv_No968_16S_rDNA        651 GCGTCAGAGGGGGGTAGAATTCCGCGTGTAGCAGTGAAATGCGTAGAGAT 700 
Cv_ATCC12472_16S_rDNA    651 GCGTCAGAGGGGGGTAGAATTCCACGTGTAGCAGTGAAATGCGTAGAGAT 700 
                             *********************** ************************** 
 
Cv_No968_16S_rDNA        701 GCGGAGGAATACCGATGGCGAAGGCAGCCCCCTGGGATGACACTGACGCT 750 
Cv_ATCC12472_16S_rDNA    701 GTGGAGGAATACCGATGGCGAAGGCAGCCCCCTGGGATGACACTGACGCT 750 
                             * ************************************************ 
 
Cv_No968_16S_rDNA        751 CATGCACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA 800 
Cv_ATCC12472_16S_rDNA    751 CATGCACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA 800 
                             ************************************************** 
 
Cv_No968_16S_rDNA        801 CGCCCTAAACGATGTCAACTAGCTGTTGGGGGTTTGAATCCTTGGTAGCG 850 
Cv_ATCC12472_16S_rDNA    801 CGCCCTAAACGATGTCAACTAGCTGTTGGGGGTTTGAATCCTTGGTAGCG 850 
                             ************************************************** 
 
Cv_No968_16S_rDNA        851 AAGCTAACGCGAGAAGTTGACCGCCTGGGGAGTACGGCCGCAAGGTTAAA 900 
Cv_ATCC12472_16S_rDNA    851 TAGCTAACGCGTGAAGTTGACCGCCTGGGGAGTACGGCCGCAAGGTTAAA 900 
                              ********** ************************************** 
 
Cv_No968_16S_rDNA        901 ACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTA 950 
Cv_ATCC12472_16S_rDNA    901 ACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTA 950 
                             ************************************************** 
 
Cv_No968_16S_rDNA        951 ATTCGATGCAACGCGAAAAACCTTACCTGGTCTTGACATGTAACGAACGC 1000 
Cv_ATCC12472_16S_rDNA    951 ATTCGATGCAACGCGAAAAACCTTACCTGCTCTTGACATGTACGGAACTT 1000 
                             ***************************** ************  ****   
 
Cv_No968_16S_rDNA       1001 CGCAGAGATGTGGTGGTGCCCGAAAGGGAGCGTTAACACAGGTGCTGCAT 1050 
Cv_ATCC12472_16S_rDNA   1001 GCCAGAGATGGCTTGGTGCCCGAAAGGGAGCCGTAACACAGGTGCTGCAT 1050 
                               ********   ******************  ***************** 
 
Cv_No968_16S_rDNA       1051 GGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG 1100 
Cv_ATCC12472_16S_rDNA   1051 GGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG 1100 
                             ************************************************** 
 
Cv_No968_16S_rDNA       1101 CGCAACCCTTGCCATTAGTTGCCATCATTAAGTTGGGCACTCTAATGGGA 1150 
Cv_ATCC12472_16S_rDNA   1101 CGCAACCCTTGTCATTAGTTGCCATCATTCAGTTGGGCACTCTAATGAGA 1150 
                             *********** ***************** ***************** ** 
 
Cv_No968_16S_rDNA       1151 CTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGG 1200 
Cv_ATCC12472_16S_rDNA   1151 CTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGG 1200 
                             ************************************************** 
 
Cv_No968_16S_rDNA       1201 CCCTTATGACCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTC 1250 
Cv_ATCC12472_16S_rDNA   1201 CCCTTATGAGCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTT 1250 
                             ********* ***************************************  
 
Cv_No968_16S_rDNA       1251 GCGAAGCCGCGAGGTGGAGCCAATCTCATAAAACCGATCGTAGTCCGGAT 1300 
Cv_ATCC12472_16S_rDNA   1251 GCCAAGCCGCGAGGTGGAGCTAATCTCAGAAAACCGATCGTAGTCCGGAT 1300 
                             ** ***************** ******* ********************* 
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Cv_No968_16S_rDNA       1301 CGCACTCTGCAACTCGAGTGCGTGAAGTCGGAATCGCTAGTAATCGCAGA 1350 
Cv_ATCC12472_16S_rDNA   1301 CGCACTCTGCAACTCGAGTGCGTGAAGTCGGAATCGCTAGTAATCGCAGA 1350 
                             ************************************************** 
 
Cv_No968_16S_rDNA       1351 TCAGCATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTC 1400 
Cv_ATCC12472_16S_rDNA   1351 TCAGCATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTC 1400 
                             ************************************************** 
 
Cv_No968_16S_rDNA       1401 ACACCATGGGAGTGAGTTTCACCAGAAGTGGGTAGGCTAACCGTAAGGAG 1450 
Cv_ATCC12472_16S_rDNA   1401 ACACCATGGGAGTGAGTTTCACCAGAAGTGGGTAGGCTAACCGCAAGGAG 1450 
                             ******************************************* ****** 
 
Cv_No968_16S_rDNA       1451 GCCGCTTACCACGGTGGGATTCAT 1474 
Cv_ATCC12472_16S_rDNA   1451 GCCGCTTACCACGGTGGGATTCAT 1474 
                             ************************ 
 
Figure 9. Alignment of 16S rDNA sequences of Chromobacterium violaceum no. 968 
(GenBank no. HM449690; result of the current work) and Chromobacterium violaceum 
ATCC 12472 (GenBank no. AE016825) by CLUSTAL W showing 96% sequence 
identity and without any gap between the two sequences. 
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Figure 10.  Examination and quantification of FK228 production by LC-MS. A, strain 
Cv WT; B, strain Cv WT under anaerobic conditions; C, strain BL21(DE3); D, strain 
SW01; E, strain SW02; F, strain SW03; G, strain SW04; H, strain SW05; I, strain SW06; 
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J, strain SW07; K, strain SW07 under anaerobic conditions; L, strain SW08; M, strain 
SW09; N, strain SW10. Detailed strain information is listed in Table 2. 
 
 
Figure 11. Alignment of FabD sequences of Chromobacterium violaceum no. 968 
(GenBank no. HM449691 for FabD1, GenBank no. HM449692 for FabD2; result of the 
current work) and Escherichia coli BL21(DE3) FabD (GenBank no.ACT42983) by 
CLUSTAL W. 
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TABLE 2. Bacterial strains and plasmids used in this study 
 
Strains or plasmids 
 
Description
a 
Source or 
reference
 
Chromobacterium 
violaceum 
no. 968 (=FERM BP-1968) 
 
Wild type strain, FK228-producing, Ap
r
 Thio
r
 
 
IPOD
b 
Escherichia coli 
DH5 
S17-1 
BL21(DE3) 
SW01 
SW02 
SW03 
 
SW04 
 
SW05 
 
SW06 
 
SW07 
 
SW08 
 
SW09 
 
SW10 
 
 
General cloning host 
Host strain for interspecies conjugation 
Host strain for heterologous gene expression 
BL21(DE3) harboring Cosmid 18 
BL21(DE3) harboring Cosmid 18 and pBMTL-3-depR 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-sfp 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-acpS 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-fabD1 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-fabD2 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-sfp-fabD1 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-sfp-fabD2 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-acpS-fabD1 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and 
pCDFDuet-1-acpS-fabD2 
 
Lab stock  
Lab stock 
Novagen 
This work 
This work 
This work 
 
This work 
 
This work 
 
This work 
 
This work 
 
This work 
 
This work 
 
This work 
Plasmids 
pGEM-3Zf 
pGEM-T Easy 
Cosmid 18 
 
pBMTL-3 
 
Ap
r
, general cloning vector 
Ap
r
, general cloning vector 
Ap
r
, Kan
r
, cosmid clone containing the FK228 biosynthetic 
gene cluster (dep) and flanking DNAs, shotgun sequenced 
Cm
r
, pBBR1 ori, broad host-range vector 
  
Promega 
Promega 
(9) 
 
(20) 
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pBMTL-3-depR 
pCDFDuet-1 
pCDFDuet-1-sfp 
pCDFDuet-1-acpS 
pCDFDuet-1-fabD1 
pCDFDuet-1-fabD2 
pCDFDuet-1-sfp-fabD1 
pCDFDuet-1-sfp-fabD2 
pCDFDuet-1-acpS-fabD1 
pCDFDuet-1-acpS-fabD2 
Cm
r
, depR (with RBS from pET29a) cloned into pBMTL-3 
Sm
r
, CDF ori, dual expression vector 
sfp cloned into the MCS1 region of pCDFDuet-1 
acpS cloned into MCS1 region of pCDFDuet-1 
fabD1 cloned into MCS2 region of pCDFDuet-1 
fabD2 cloned into MCS2 region of pCDFDuet-1 
sfp cloned into MCS1, fabD1 cloned into MCS2 of 
pCDFDuet-1 
sfp cloned into MCS1, fabD2 cloned into MCS2 of 
pCDFDuet-1 
acpS cloned into MCS1, fabD1 cloned into MCS2 of 
pCDFDuet-1 
acpS cloned into MCS1, fabD2 cloned into MCS2 of 
pCDFDuet-1 
(23) 
Novagen 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
 
a
 Ap
r
, ampicillin resistance; Cm
r
, chloramphenicol resistance; Kan
r
, kanamycin 
resistance; Sm
r
, streptomycin resistance; Thio
r
, thiostrepton resistance; MCS, multiple 
cloning site. 
b
 IPOD, International Patent Organism Depositary, Tsukuba, Japan. 
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TABLE 3. Candidate genes identified through rapid genome sequencing and their 
involvement in FK228 biosynthesis 
Gene Name
a
 Deduced Product and Predicted 
Function
 
Gene 
Disposability 
Involvement in 
FK228 
Biosynthesis
 
AT-encoding genes 
fabD1 
 
fabD2 
AT3 
 
PPTase-encoding 
genes 
acpS 
 
sfp 
 
FabD1, likely involved in fatty acid 
biosynthesis 
FabD2, function unpredictable a priori 
AT3, likely involved in cell-surface O-
antigen biosynthesis 
 
AcpS-type PPTase, likely involved in 
primary metabolite biosynthesis 
Sfp-type PPTase, likely involved in 
secondary metabolite biosynthesis 
 
No 
 
No 
Yes 
 
 
No 
 
No 
 
Positive 
 
Positive 
No 
 
 
No 
 
Yes 
a
 AT, acyltransferase; PPTase, phosphopantetheinyltransferase. 
 
  TABLE 4. Primers used for gene deletion, genotype detection and detection of gene   
expression 
Name (primers sorted 
by gene) 
Sequence (5’  3’)a Gene 
Deletion 
KpnI-NdeI-fabD1-
UpF 
FRT-F-fabD1-UpR 
FRT-R-fabD1-DnF 
BamHI-fabD1-DnR 
fabD1-RT-PCR-FP 
fabD1-RT-PCR-RP 
AGGTACCCATATGgcgtttgcatttctgttcc 
TCAGAGCGCTTTTGAAGCTAATTCGtt
caactcctgccaggcc 
AGGAACTTCAAGATCCCCAATTCGcca
gctacaccgagcc 
CTGGATCCtcagttcagttcgccgcgag 
(Same as KpnI-NdeI-fabD1-UpF) 
(Same as FRT-F-fabD1-UpR) 
Not 
successful 
KpnI-NdeI-fabD2-
UpF 
FRT-F-fabD2-UpR 
FRT-R-fabD2-DnF 
HindIII-fabD2-DnR 
fabD2-RT-PCR-FP 
fabD2-RT-PCR-RP 
AGGTACCCATATGctgcgccgcttgccgaa 
TCAGAGCGCTTTTGAAGCTAATTCGat
ggaaagccccgccac 
AGGAACTTCAAGATCCCCAATTCGcgt
gggaacgcggcatg 
CTAAGCTTcatgtaccacttgaccattcc 
(Same as KpnI-NdeI-fabD2-UpF) 
(Same as FRT-F-fabD2-UpR) 
Not 
successful 
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KpnI-NdeI-AT3-UpF 
FRT-F-AT3-UpR 
FRT-R-AT3-DnF 
BamHI-AT3-DnR 
AT3-RT-PCR-FP 
AT3-RT-PCR-RP 
AGGTACCCATATGgcgtttgcatttctgttcc 
TCAGAGCGCTTTTGAAGCTAATTCGc
gtagaatgccttgaagtc 
AGGAACTTCAAGATCCCCAATTCGtcg
cctgcaaattgttcag 
CTGGATCCttagcgttcggcgcttcttgc 
(Same as KpnI-NdeI-AT3-UpF) 
(Same as FRT-F-AT3-UpR) 
Successful 
KpnI-NdeI-acpS-UpF 
FRT-F-acpS-UpR 
FRT-R-acpS-DnF 
HindIII-acpS-DnR 
acpS-RT-PCR-FP 
acpS-RT-PCR-RP 
AGGTACCCATATGatttacggcattggcactg 
TCAGAGCGCTTTTGAAGCTAATTCGa
aacgcttggccaggaag 
AGGAACTTCAAGATCCCCAATTCGctt
agccccgaattggaag 
CTAAGCTTctagccgggcgcggagcg 
(Same as KpnI-NdeI-acpS-UpF) 
(Same as FRT-F-acpS-UpR) 
Not 
successful 
KpnI-NdeI-sfp-UpF 
FRT-F-sfp-UpR 
FRT-R-sfp-DnF 
HindIII-sfp-DnR 
sfp-RT-PCR-FP 
sfpRT-PCR-RP 
AGGTACCCATATGgaactgaacgctttgatcaag 
TCAGAGCGCTTTTGAAGCTAATTCGc
caacagccgtcgtagtg 
AGGAACTTCAAGATCCCCAATTCGga
gcagaccttgctgcc 
CTAAGCTTcagccctccgcccaggc 
(Same as KpnI-NdeI-sfp-UpF) 
(Same as FRT-F-sfp-UpR) 
Not 
successful 
16S-RT-PCR-F 
16S-RT-PCR-R 
gactcctacgggaggcagc 
gtattaccgcggctgctggc 
N/A 
depA-RT-PCR-F 
depA-RT-PCR-R 
cacctcggggtccacgcg 
gggaaaaccgcattgcaaggg 
N/A 
depJ-RT-PCR-F 
depJ-RT-PCR-R 
tgctttccgtatgcgggcgg 
ctcgcgcccatgctgtgccc 
N/A 
depR-RT-PCR-F 
depR-RT-PCR-R 
gaacttcgctatatcgtcgcg 
gctgcgattgctcgatgatgc 
N/A 
 
a
Sequences in capital letters are designed either to provide restriction sites (underlined) 
for directional cloning, or to provide extra base(s) in front of restriction sites for efficient 
restriction enzyme digestion, or to provide overlapping sequences for FRT cassette 
assembly during multiplex PCR. Lower-case letters indicate gene-specific sequences 
used for amplification of individual genes. 
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Table 5. Quantification of FK228 production by recombinant E. coli strains relative to the 
wild type strain of Chromobacterium violaceum no. 968 cultivated under aerobic conditions 
unless indicated by * for under anaerobic conditions. Experiments were performed in 
duplicate and the data are presented as mean values with standard deviation. 
 
Strains 
 
Description
a 
Relative level 
of FK228 
Production 
(%)
 
Chromobacterium 
violaceum 
no. 968 (=FERM BP-1968) 
no. 968* 
 
Wild type, FK228 producing 
(Same as above) 
  
100.0 
6.76.2 
Escherichia coli 
SW01 
SW02 
SW03 
 
SW04 
 
SW05 
 
SW06 
 
SW07 
 
SW07* 
SW08 
 
SW09 
 
SW10 
 
 
BL21(DE3) harboring Cosmid 18 
BL21(DE3) harboring Cosmid 18 and pBMTL-3-
depR 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-sfp 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-acpS 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-fabD1 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-fabD2 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-sfp-fabD1 
(Same as above) 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-sfp-fabD2 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-acpS-fabD1 
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR 
and pCDFDuet-1-acpS-fabD2 
 
0.0 
0.0 
 
46.310.2 
 
0.0 
 
0.0 
 
0.0 
 
92.25.8 
 
14.18.4 
86.310.1 
 
0.0 
 
0.0 
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CHAPTER 3 
 
ENGINEERING A NOVEL SECRETION SYSTEM FOR PRODUCTION AND 
DIRECT PURIFICATION OF ANTICANCER CELL PENETRATING PEPTIDES 
FROM THE MEDIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Content of this chapter is a reformatted version of a manuscript to be submitted to the 
journal of Applied and Environmental Microbiology. 
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3.1. Abstract  
 Cell penetrating peptides (CPPs) are short peptides that possess the unique 
capacity to translocate across cell membranes.  Recently, a CPP derived from a virulence 
protein associated with the type III secretion system of Yersinia enterocolitica was 
identified and shown to be important in bacterial pathogenicity.   Here, we show the 
construction of a fusion protein combining the transmembrane activity of a bacterial CPP 
with a eukaryotic mitochondrial disrupting protein (MDP) to produce a new CPP-MDP 
protein with anticancer activity.  We also show the creation of a new E. coli BL21(DE3)-
based expression system that facilitates the secretion of CPP fusion proteins into the 
growth media for rapid and efficient protein purification.  This protein secretion system 
utilizes induced L-form bacterial spheroplasts to generate a yield of 32 mg/L of CPP-
MDP directly from the media.  Construction of an L-form based E. coli BL21 (DE3) 
protein secretion system and a modular CPP expression system allows future rapid CPP-
fusion protein production with new fusion protein partners to develop new CPP-based 
anticancer agents.   
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3.2. Introduction 
 Protein secretion directly into the surrounding growth media offers many 
advantages for recombinant protein production.  However, traditional laboratory strains 
of E. coli do not typically secrete proteins prompting development of new strategies for 
protein secretion.  Currently, four strategies have been developed to release recombinant 
proteins into the media.  The first involves the engineering of pathogenic strains of E. coli 
to link recombinant protein expression with one of the six dedicated protein secretion 
pathways, with the Type I secretion pathway most often targeted (1).   The second 
strategy involves the use of carrier proteins like the IgG binding domain fused with 
recombinant protein A, but the mechanism for release is unknown (2).  The third strategy 
exploits cell wall structural deficits produced by mutations targeting the gene regulating 
cell wall biosynthesis and division (3).  One drawback to this approach is the decrease in 
cell growth limiting the overall protein production.  Finally, the fourth strategy involves 
cell lysis through the co-expression of Kil protein with the recombinant protein (4).  
However, this strategy utilizing cell membrane disruption lowers the cell density and 
does not insure the proper folding of recombinant proteins. 
 One of the major inhibitors of recombinant protein secretion in E. coli is the 
presence of the cell wall.  While not critical for cell survival, the bacterial cell wall plays 
many important roles in a bacterial growth and survival.  Not only is the cell wall 
important in protection, but also functions in cell morphology, cellular adhesion and cell 
to cell communication.  However, under certain circumstances bacteria will lose all or 
part of their cell wall producing osmo-sensitive variants.  These cell wall defective 
bacteria (CWDB) can be generated in vitro and in vivo in many species and has been 
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suggested to be a survival strategy utilized by bacteria to negate cell wall-targeting 
antibiotics and evade recognition by the immune system (5,6).  CWDB can be classified 
into four groups (stable vs. unstable, spheroplast vs. protoplast) based on their ability to 
grow on specialized osmotically balanced media (7).  Stable L form bacteria are formed 
through genetic mutation resulting in a physiologically different offspring incapable of 
reverting back to a classical parental form possessing a cell wall (8).   Therefore, stable L 
form CWDB are genetically different from their parent strain.  In contrast, unstable L 
forms retain their ability to revert back to the parental form and are considered 
genetically identical to the parent strain (9).  Also, L forms can be further classified as 
spheroplasts or protoplasts. Cells that retain a residual cell wall are defined as 
spheroplasts, while those cells completely lacking a cell wall are protoplasts. Finally, L 
form bacteria exhibit a classic "fried egg" appearance when grown on solid media but L 
form manipulation may also be performed in liquid media.   
 Currently, renewed interest in L form bacteria has occurred due to their 
association with antibiotic resistance and certain disease states.   L form bacteria gain 
many advantages including resistance to cell wall-targeting antibiotics, resistance to 
bacteriophage infection and faster growth in nutrient rich environments at the cost of 
losing mobility (lacking fimbrae and flagella) (7-13).  In contrast, L form bacteria 
develop the disadvantage of osmotic sensitivity and lose genetic transfer ability by 
conjugation.   In E. coli, the relA, spoT, creC and metB mutations were identified in the 
formation of the stable L form strain LW1655F+ (7).  Further research showed that 
mutations also existed in critical cell division genes in the dcw cluster in stable L form 
bacteria.  Therefore, L form bacteria represent a unique convertible phenotype that may 
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offer the bacteria various advantages to adapt to a changing environment, including 
oxidative stress and DNA damage.  Staphylococcus aureus was shown to form unstable L 
forms and developed  beta-lactam resistance in revertants  (8).  Genetic analysis of E. coli 
unstable L forms undergoing cell division identified regulatory and structural colanic acid 
mutants and an mrcB penicillin-binding protein (PBP) 1B mutant defective in L form 
development (9). Furthermore, preliminary whole genome transcriptome analysis of  E. 
coli mutants defective in L form development showed these mutations were also critical 
in DNA repair, oxidative stress response and acid tolerance pathways (13).   
 Since the discovery of cell penetrating peptides in 1988, new attributes and 
functions have been identified demonstrating broad therapeutic applications.  
Structurally, cell penetrating peptides (CPPs) are composed of relatively short basic 
sequences of 5 to 40 amino acids and possess the ability to cross the cell membrane 
through a number of mechanisms.  While all CPPs share membrane translocation activity 
the entry mechanisms may differ.  The CPP membrane translocation process appears to 
be dependent on the cell type and the cargo that may be conjugated to the CPP (14).   
Recent studies suggest that most CPPs enter eukaryotic cells through endocytosis uptake 
mechanisms, however small arginine-rich CPPs have been shown to cross the plasma 
membrane in an energy independent process (15).  CPPs can utilize both the clathrin-
dependent and clathrin-independent endocytosis pathways to gain entrance into the cell 
and are able to escape from the endosomes to the cytoplasm.  Translocation from the 
endosome appears to be facilitated by endosome acidification allowing the CPP to cross 
the lipid bilayer (14, 16, 17).   Recently, YopM, a protein associated with Yersinia 
enterocolitica infection, was shown to have cell translocation capability.  Normally, 
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YopM and other pathogenic proteins pass through the cell membrane via the type III 
secretion system (T3SS).  This activity was attributed to two highly cationic amino acid 
regions within two alpha helices in the N-terminus and demonstrated the ability to 
translocate a fused protein cargo across the cellular membrane (18).   
The transmembrane activity of CPPs and CPP fusion proteins represents new engineering 
opportunities with vast therapeutic applications.  CPPs have been shown to deliver a 
variety of cargo including short inhibiting RNA, plasmids, proteins, liposomes, drugs and 
fluorescent markers, and represent a powerful strategy for drug delivery.  This strategy 
can be used to increase cancer cell activity of these anticancer agents by facilitating their 
delivery into tumor cells. Furthermore, the CPP transmembrane activity showed that drug 
resistant cancer cells could be reverted back to a drug sensitive phenotype by conjugating 
CPP with Taxol and other known anticancer drugs by increasing intracellular drug 
concentrations (19).  Also, CPPs conjugated with protein or protein domains can be used 
to specifically target pathways associated with a pro-cancer cell state or apoptosis 
pathways leading to cell death of cancer cells.  While cell targeting for most CPPs is 
ambiguous, recent studies identified CPPs with tumor targeting capabilities (20).  Finally, 
fluorescent labeled-CPP conjugates have been developed for surgical cancer therapy.  
The fluorescent-CPP with an antibody specific for the cancer cells facilitates the 
endosomal escape of the conjugate preserving the fluorescent signal within the cancer 
cell cytoplasm for easy surgical removal of only tumor tissue (21). Therefore, these 
unique peptides offer a variety of engineering options for the development of new 
anticancer agents and many other therapeutic applications. 
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 However, many challenges remain to efficiently express and purify functional 
CPPs and recombinant proteins in E. coli systems.  While CPPs can be chemically 
synthesized and purified from inclusion bodies, but both strategies have drawbacks 
related to proper protein folding and function.  Also, the chemical synthesis strategy 
continues to cost more than traditional E. coli expression and purification systems 
expanding costs to downstream applications. In contrast, protein secretion to the media 
has the advantage of preserving protein structure; however secretion pathways are limited 
due to the cell wall barrier.  Secretion of CPP fusion proteins to the periplasm may allow 
the translocation of the CPP fusion protein to the media or production of cell wall 
deficient L form strains could be generated to directly secrete CPP fusion proteins into 
the media.   Here we describe the generation of unstable L form spheroplasts that allowed 
secretion to the media and subsequent purification of a CPP fusion protein with broad 
anticancer activity.   
 
3.3. Materials and Methods 
 
3.3.1. Bacterial strains, plasmids, culture conditions, and general molecular biological 
manipulations. 
 The bacterial strains and plasmids used in this study are listed in Table 6. Culture 
conditions for general molecular biological manipulations were performed as described 
(22), or according to standard protocols (23).  Primers used to amplify and synthesize the 
corresponding DNA sequences are listed in Table 7.  The yopM75 sequence was amplified 
from genomic Yesinia enterocolitica O8 strain JB580v DNA.  Sequential addition of 
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ompF and MDP DNA sequences were constructed using a two-step overlap Phusion

 
DNA polymerase (New England Biolabs) PCR protocol using 20 nM of each synthesis 
primer and target yopM75 sequence for five PCR cycles.  After five cycles, each 
amplification primer was added to a final concentration of 0.5 M to the reaction mixture 
to synthesize the full length product.  The PCR products and pET29a plasmid were 
digested with NdeI and XhoI and ligated to produce the final vector constructs with the 
ompF signal sequence and MDP sequence added to yopM75 in pET29a vector (Table 6).  
The sequences of the modular expression cassette are listed in Table 8. 
 
3.3.2. Protein purification and protein identification by Western blot analysis. 
 Wild-type E. coli BL21 (DE3) and E. coli BL21 (DE3) containing the  pET29-
ompF-yopM75-MDP construct were grown at 37˚C in LB or Pennassay L form production 
media containing 40 g/ml of kanamycin and were induced with 0.5 M IPTG (isopropyl 
β-D-1-thiogalactopyranoside, Sigma Aldrich) during mid-log phase.  Protein samples of 
whole cell, cell pellet, cell cytoplasm supernatant, periplasmic proteins and media 
secreted protein fraction were prepared according to standard protocols (23).  Protein 
samples were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and analyzed by Western blotting.  Polyclonal immunoglobulin antibody 
against 6X His tag prepared from mouse was used as the probe and was incubated with E. 
coli BL21 (DE3) control and the expressed protein samples.  BCIP/NitroBT (Sigma 
Aldrich) substrate was used to detect an anti-mouse secondary antibody conjugated with 
alkaline phosphatase. 
 
68 
 
 
 
3.3.3. Development of L form bacteria protein secretion system and protein quantification 
 E. coli BL21 (DE3)/pET29-ompF-yopM75-MDP and E. coli BL21 (DE3)/pET29 
constructs were grown at 37˚C in Pennassay media containing 40 µg/ml of kanamycin.  
Mid-log phase cultures were incubated with 50 L of 5 mg/mL lysozyme for 2 hours.  
Cultures were then induced with 0.5 M IPTG and incubated at 37˚C for 6 to 8 hours.  E. 
coli BL21 (DE3) constructs were maintained on Pennassay 1.5% agarose media 
containing 40 µg/ml and 25 µg/ml ampicillin.  Media fractions were separated by 
ammonium sulfate precipitation.   The 0-40% ammonium sulfate (AS) fraction was 
discarded and the 40-70% AS fraction was resuspended in 500 mL of 20 M phosphate 
buffer, pH 6.8, and desalted with a ZEBA spin column (Pierce).  Desalted samples were 
resuspended in 50 mL of 20 M phosphate buffer, pH 6.8 and filtered with a 0.2 micron 
filter (Millipore).  Manual sample protein purification was performed using a Mono S 
5/50 GL cation exchange column (GE Healthcare) on an ÄKTA FPLC (GE Healthcare) 
with 20 M phosphate buffer pH 6.8 system.  Samples were washed with buffer A, 20 
M phosphate buffer pH 6.8 and eluted by increasing NaCl gradient of buffer B, 20 M 
phosphate buffer pH 6.8 with 1 M NaCl.  Elution sample concentrations were determined 
using Bradford’s reagent (Sigma Aldrich) and comparison to a bovine serum albumin 
(BSA) (Sigma Aldrich) standard curve.  The elution samples were then pooled together 
and the concentration was determined using the Bradford reagent method and lyophilized 
(Labconco).  10 mg stocks were preserved in 50% glycerol and stored at -20˚C. 
 
3.3.4 Cancer cell cultures, MTT viability and apoptosis assays 
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 Cytotoxicity of O75M to DU-145, H232A and MDA-MB-231 cells was studied 
using the MTT assay. First, cells (5 × 10
4
) were incubated for 24 h in RPMI 1640 
supplemented with 10% FBS and 2 mM L-glutamine.  A serial dilution (100 M to 1 
nM) from the media purified O75M 10 mg stock was generated was generated with a 
final glycerol concentration of 0.5%.  Thereafter, the cells were washed and plated with 
O75M samples in triplicate in 96-well plates and cultured for 48 h. The cells were then 
incubated for 4 h with RPMI 1640 containing 250 µg/mL of MTT. After discarding the 
culture medium, 200 µL of DMSO was added to dissolve the precipitates, and the 
resulting solution was measured for absorbance at 570 nm with a reference wavelength of 
690 nm using an Infinite200Pro plate reader (Tecan). Significant differences between 
samples in cytotoxicity between treatment groups were determined using a two-tailed 
Student's t-test with p < 0.05 being considered significant.  Apoptosis analysis was 
performed with ApoTox-Glo Triplex Assay kit (Promega) and results analyzed for 
fluorescence and luminescence with the Infinite200Pro plate reader (Tecan). 
 
 
 
3.4. Results and Discussion 
 
3.4.1. Cell penetrating peptide synthesis and secretion model design. 
 Development of a functional E. coli CPP expression system allows rapid CPP-
fusion protein production for a broad CPP based anticancer agent production program.  
The CPP expression system was designed to utilize both ligation and DNA synthesis 
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approaches to develop functional CPP and CPP fusion protein products.   Previous 
identification of transmembrane activity in the N-terminal α-helices of YopM, a T3SS 
protein associated with Salmonella enterocolitica infection, provided a CPP from a 
bacterium that was capable of  expression in E. coli BL21(DE3), albeit in inclusion 
bodies (18).  Primers designed to amplify the first 73 amino acids of yopM, associated 
with the two N-terminal α-helices with two extra C-terminal amino acids used as a linker 
for addition of a protein cargo allow the CPP to be cloned into pET29a.  Addition of 
ompF signal sequence to export the CPP/CPP cargo peptide via cellular secretion 
pathways was designed to use a primer overlap PCR strategy with the 5' end of the yopM 
sequence.  Also, a DNA synthetic approach was used to add the mitochondrial disrupting 
peptide (MDP) sequence through overlapping primers complementing the 3' end of the 
yopM75 sequence.  The MDP sequence was previously reported to have cancer 
cytotoxicity inducing apoptosis (24).  The final ompF-yopM75-MDP construct will be 
cloned into pET-29a to produce the expression vector pET-29-ompF-yopM75-MDP (Fig. 
12A; Fig. 12B). Utilizing the NdeI and XhoI restriction enzymes allows expression of the 
CPP fusion protein with a C-terminal 6x His-tag.  The addition of the 6x His-tag CPP can 
be used both in purification and identification of the CPP-fusion protein by Ni-NTA 
column and Western blot, respectively.    The addition of the ompF signal sequence 
directs the nascent CPP to the Type I secretion pathway for export into the periplasm and 
ultimately into the media for purification (25).  Export of CPP proteins into the periplasm 
allows bi-direction transmembrane activity of the CPP to partially or completely escape 
into the media for purification.  Furthermore, this model accounts for alternate methods 
for the release of the CPP construct into the media.  Possible strategies for the cellular 
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CPP release include the addition of cell wall permeabilization agents like glycerol or 
formation of L-form E. coli BL21(DE3) spheroplast or protoplast expression strains to 
facilitate or increase CPP secretion into the media (26). 
 
Figure 12.  Model of CPP secretion system.  (A) Expression cassette modular design 
with an inducible promoter, ompF signal sequence, CPP (yopM75) and MDP 
(mitochondrial disrupting peptide).  (B) Plasmid pET29-ompF-yopM75-MDP construct 
with kanamycin resistance.  (C) OmpF signal sequence directed Type I secretion pathway 
export of CPP to periplasm and release into the media.  (D) Increased CPP export into the 
media can be achieved by agents that increase outer membrane permeability or degrade 
the cell wall.  (IM, inner membrane; PG, peptidoglycan; OM, outer membrane) 
 
3.4.2. Identification, cloning and expression of potential cell penetrating peptides. 
 Construction of a CPP with anticancer activity was based on the model design.  
First, yopM75 was amplified by PCR, digested with NdeI/XhoI and ligated into the NdeI 
and XhoI sites of pET-29a. The pET-29a-yopM75 construct was used to transform E. coli 
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DH5α and were verified by sequencing.  Next, the ompF signal sequence and 
mitochondrial disrupting peptide sequence (MDP) were added using an overlap primer 
extension PCR method to synthesize the ompF-yopM75-MDP construct was digested with 
NdeI/XhoI and ligated into NdeI/XhoI sites of pET29a (Table 7).  Sequence verified 
pET29a- ompF-yopM75-MDP constructs were used to transform the expression strain, E. 
coli BL21 (DE3).  Protein expression experiments with E. coli BL21 (DE3)/pET29a- 
ompF-yopM75-MDP and control strain E. coli BL21 (DE3)/pET29a were performed in 50 
mL cultures and induced with IPTG during mid-logarithmic growth.  Whole cell fractions 
containing the media, cytoplasm and membrane fractions were analyzed by SDS-PAGE 
gels to determine protein expression.  The whole cell fraction showed the presence of a 
13 kDa band visible in the IPTG induced sample (Fig. 13).  After cell lysis, a similar 
band was found in the cell pellet fraction consisting of insoluble membrane protein and 
protein inclusion bodies showing the CPP-fusion protein was expressed but packaged 
into inclusion bodies (Fig. 13).  This result also showed the OmpF-YopM75-MDP protein 
was expressed, but the signal sequence was not cleaved in the whole cell or the cell pellet 
inclusion body fraction accounting for the increase in molecular weight.   Next, the 
periplasmic fraction was examined for protein secretion and in contrast to the cell pellet 
fraction, the periplasmic fraction showed an 11 kDa band related to the YopM75-MDP 
protein secreted into the periplasm (Fig. 13).  This result demonstrated the functional 
activity of the OmpF signal sequence directing protein secretion to the periplasm and the 
cleavage of the signal sequence upon entering the periplasm.  However, examination of 
the media for the presence of the YopM75-MDP did not show the release of the protein 
through the outer membrane into the media.   Previous studies demonstrated the 
73 
 
 
 
localization and accumulation of OmpF signal proteins in the periplasm and counter 
reports of extracellular secretion. (25)  This result supports the notion that the formation 
of inclusion bodies was due to the accumulation of protein in the periplasm and did not 
release the protein into the extracellular media due to periplasm crowding.  However, 
protein expression from a strong promoter like the T7 promoter may offset the balance 
between secretion protein synthesis and secretion pathway periplasm export.   Also, the 
increase inclusion body formation may be a cellular reaction to the cytoplasmic 
accumulation of OmpF-YopM75-MDP with inherent toxic properties or induced toxicity 
from accumulation.  
 
 
Figure 13.  YopM75-MDP expression and secretion to the media.  The initial expression 
analysis of the whole cell (WC) fraction showed YopM75-MDP at 13 kDa.  Further 
analysis showed YopM75-MDP formed inclusion bodies isolated in the cell pellet (Pt) 
also at 13 kDa correlating with the YopM75-MDP still possessing the OmpF, signal 
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sequence.  In contrast, soluble YopM75-MDP was not detected in the cytoplasm 
supernatant (Sn) fraction.  Examination of the periplasm showed secretion and 
accumulation of YopM75-MDP at 11 kDa, related to the excision of OmpF during 
secretion.  Initial YopM75-MDP was not detected from the media, however when cells 
were treated with lysozyme the 11 kDa band was present and corresponded to the release 
of YopM75-MDP into the media.  
 
3.4.3. Development of L form E. coli, secretion of peptides to the media and purification. 
 The secretion of proteins into the media has been extensively researched and often 
requires the addition of membrane permeabilization molecules or cell wall disruption 
agents.  Previous protein export attempts report using molecules like glycerol increase the 
diffusion rate of proteins through the cell wall, but the diffusion rates to the growth media 
remained slow (26).  Therefore, cell wall disrupting agents like penicillin or lysozyme 
appear to be the best suited agents for high yield protein secretion systems.  The addition 
of these agents leads to the degradation of the peptidoglycan layer and either partial or 
complete removal of the outer membrane in the production of L-form bacterial 
spheroplasts or protoplasts, respectively.  In order to construct active protein expression 
L-form E. coli BL21(DE3)/ pET29a-ompF-yopM75-MDP cells, 50 mL Penassay broth 
media cultures were grown to mid-logarithmic growth and 50 µL of 5 mg/mL lysozyme 
stock was added and incubated for 2 hours prior to induction with final IPTG 
concentration of 0.5µM.  Lysozyme treated and non-treated cultures were streaked on 
Pennassay L-form agar media containing kanamycin and ampicillin to compare culture 
morphology.  Kanamycin was used for selection of strains carrying the pET29 construct, 
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while a serial dilution of ampicillin was used to test for L-form phenotype demonstrating 
increased resistance to peptidoglycan targeting antibiotics like ampicillin.  The remaining 
culture was analyzed for protein secretion into the media.  
 
Figure 14.  Formation of L form BL21 (DE3) E. coli.  Parental E. coli BL21 (DE3) 
colonies demonstrate tan colonies with distinct boundries (A), while lysozyme treated E. 
coli BL21 (DE3) formed white/milky mucoid colonies depicting L form phenotype (B).  
Morphology analysis by TEM at 17,000X showed parental E. coli BL21 (DE3) cells as 
76 
 
 
 
smooth rod shaped bacteria (C).  In contrast, L form E. coli BL21 (DE3) showed a round, 
cocoid bacteria with frayed outermembrane and the presence of membrane blebs (D). 
 
Examination of the cell culture morphology showed a difference between lysozyme 
treated and non-lysozyme treated cells.   Lysozyme treated cell formed large white and 
tan mucoid colonies with undefined boundaries, while the untreated cells formed tan oval 
colonies with defined boundaries (Fig 14A; Fig. 14B).  Next, the cell phenotype was 
analyzed by TEM to identify the presence of L-form spheroplasts or protoplasts.  TEM 
micrographs of lysozyme treated sample showed the presence of round cells, with partial 
attachment of the outer membrane and membrane blebbing (Fig. 14D).  In comparison, 
the untreated cells were rod shaped with a smooth outer membrane (Fig. 14C).  These 
results, showed the formation of L-form spheroplasts from E. coli BL21 (DE3)/ pET29a- 
ompF-yopM75-MDP cells with similar colony morphology and cellular phenotypes to 
previously described L form bacteria (13). 
Comparison of media fractions between lysozyme treated cultures and non-lysozyme 
treated cultures showed the presence of an 11 kDa protein in the lysozyme treated 
cultures.  This protein correlates with the protein identified in the periplasmic fraction of 
similar molecular weight (Fig. 13).  This protein was purified by anion exchange 
chromatography with a yield of 32 mg/L and produced an elution protein at 11 kDa 
correlating to both the periplasmic and media fractions (Fig. 15).  This protein was 
confirmed by antibody detection of the C-terminal His tag using Western blot analysis, 
which verified the presence of YopM75-MDP in the media post lysozyme treatment.  
Next, the elution samples were pooled and dialyzed to reduce contaminating salt 
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concentrations.  The pooled sample was concentrated by lyophilization and resuspended 
in 50% glycerol for storage.  The purification of YopM75-MDP represents a fast and 
efficient strategy for the secretion and purification of CPP fusion proteins by utilizing the 
unique cell wall deficiencies of L form E. coli BL21 (DE3) cells.  The rapid generation of 
CPPs and CPP fusion proteins can be used to produce therapeutic concentration and test 
for novel activities. 
 
Figure 15.  Purification of YopM75-MDP from the media.  The prepared media fractions 
were separated and purified by anion exchange chromatography yielding a single band at 
11 kDa corresponding to YopM75-MDP (*).  
 
3.4.4. Antiproliferative activity of CPP. 
 Cancer cell viability screening demonstrated YopM75-MDP antiproliferative 
activity toward lung, breast and prostate cancer cell lines.  Purified YopM75-MDP was 
used for MTT cell viability assays and determined the antiproliferative activity IC50 value 
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in the low µM range for each cancer cell type.  The IC50 values were calculated to be 2.47 
± 0.2µM, 3.27 ± 0.2µM and 6.99 ± 0.12µM for DU-145 prostate cancer cells, H232A 
lung cancer cells and MDA MB-231 breast cancer cells, respectively (Fig. 16).  The DU-
145 prostate cancer cell viability assay result was further supported by the Apo-Tox-Glo 
result.  The IC50 was calculated to be 3.99 ± 0.2µM and was similar to the MTT assay 
result.  The toxicity assay showed similar fluorescence to the control demonstrating the 
cells were not rapidly lysing.  While, caspase 3/7 activity increased with increasing 
concentrations of YopM75-MDP demonstrating the induction of apoptosis through the 
induction of the caspase cascade (Fig. 17).   These results show similar cytotoxicity 
toward cancer cell lines, while reducing toxicity toward E. coli (24).  The MDP sequence 
bears high sequence similarity to synthetic antimicrobial peptides that exhibited 
cytotoxicity toward E. coli and 3T3 mouse embryonic fibroblasts (27).  The addition of a 
CPP that originated in Yersinia enterocolitica, a relative of E. coli, would suggest that 
antimicrobial activity may be reduced toward bacteria through the fusion of YopM75.  
Furthermore, the activity of YopM75-MDP provides further evidence of the vast potential 
of CPP fusion proteins.  The purification of YopM75-MDP from the media demonstrated 
the ability to generate novel E. coli L form expression systems with lysozyme treatment 
to release OmpF based signal proteins.  Finally, the formation of E. coli L form protein 
secretion cells advances our goal toward generating CPP expressing anticancer bio-agents 
capable of intra-tumor growth and anticancer protein expression. 
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Figure 16.  Cancer cell antiproliferation assays.  YopM75-MDP was tested for activity 
against three cancer cell lines. (A) prostate cancer cell line DU-145, (B) breast cancer cell 
line H232A, (C) lung cancer cell line MDA MB-231. 
 
Figure 17.  Apoptosis pathway induction assay.  YopM75-MDP showed induced caspase 
activity in prostate cancer cell line DU-145.  Also, YopM75-MDP did not show increased 
toxicity, while demonstrating similar cell viability results to the MTT analysis. 
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Table 6. Bacterial strains and plasmids used in this study 
 
Strains or plasmids 
 
Description
a 
Source or 
reference
 
Yesinia enterocolitica O8 
      strain JB580v 
 
Wild type strain 
 
 
 
Escherichia coli 
DH5 
BL21(DE3) 
SW01 
SW02 
 
 
General cloning host 
Host strain for heterologous gene expression 
BL21(DE3) harboring pET29 
BL21(DE3) harboring pET29-ompF-yop75-MDP 
 
 
Lab stock  
Novagen 
This work 
This work 
 
Plasmids 
pET29 
pET29-yop75 
pET29-ompF-yop75 
pET29-ompF-yop75-MDP 
 
Kan
r
, general cloning vector 
Kan
r
, yop75 CCP cloned into MCS 
Kan
r
, yop75 with ompF signal sequence 
Kan
r
, yop75 with ompF signal sequence and MDP gene 
sequence 
  
Novagen 
This study 
This study 
This study 
a
 Kan
r
, kanamycin resistance; MCS, multiple cloning site; MDP, mitochondrial disrupting peptide. 
b
strain was provided as a gift by Dr. Kristen Walker, University North Carolina (UNC) School of Medicine. 
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Table 7. Primers used for construction of CPPs and gene expression 
Name (primers sorted by 
gene) 
Sequence (5’  3’)a Gene Name 
FP-yop75-NdeI    
RP-yop75-BamHI-XhoI 
CTAGCACATATGTTTATAACTCCAAGAAATGTATC  
CGCTCGAG GGATCCGGCTTGTCGGTCCAGGC 
yop75 
Amplification primer 
FP-OmpF-SRP OV-NdeI 
 
Synthesis primers 
FP-OmpF-SRP OV2 
 
RP-OmpF-SRP OV   
 
CTAGCACATATGATGATGAAGCGCAATATTCTG  
 
 
GCTCTGTTAGTAGCAGGTACTGCAAACGCTTTTAT
AACTCCAAGAAATGTATC 
TGCAGTACCTGCTACTAACAGAGCAGGGACGATC
ACTGCCAGAATATTGCGCTTCATCAT 
 
ompF signal 
sequence 
Amplification primer 
RP-MDP-CPP-XhoI   
 
Synthesis primer 
RP-CPP-MDP-OV   
 
 
CCCTCGAGTTTCGCCAGTTTCGCCAG 
 
 
TTTCGCCAGTTTCGCCAGTTTTTTCGCCAGTTTCGC
CAGTTT GGCTTGTCGGTCCAGGC  
 
 
MDP 
a
Sequences in capital letters are designed either to provide restriction sites (underlined) 
for directional cloning, or to provide extra base(s) in front of restriction sites for efficient 
restriction enzyme digestion, or to provide overlapping sequences for CPP expression 
cassette assembly during multiplex PCR. 
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Table 8. DNA and Protein sequences  
Name of Sequence Sequence (5’  3’)a 
ompF signal sequence ATGATGAAGCGCAATATTCTGGCAGTGATCGTCCCTGCTCTGTTA
GTAGCAGGTACTGCAAACGCT 
OmpF signal sequence MMKRNILAVIVPALLVAGTANA 
yopM75 
  
ATGTTTATAACTCCAAGAAATGTATCTAATACTTTTTTGCAAGAAC
CATTACGTCATTCTTCTGATTTAACTGAGATGCCGGTTGAAGCAG
AAAATGTTAAATCTAAGACTGAATATTATAATGCATGGGCGGTAT
GGGAACGAAATGCCCCTCCGGGGAATGGTGAACAGAGGGAAATG
GCGGTTTCAAGGTTACGCGATTGCCTGGACCGACAAGCCGGATCC
TCTAGAGTCGACCTGCAGGCATGCAAGCTTGCGGCCGCACTCGAG
CACCACCACCACCACCACTGAGATCCGGCTGCTAACTCGAC  
YopM75 MFITPRNVSNTFLQEPLRHSSDLTEMPVEAENVKSKTEYYNAWAVW
ERNAPPGNGEQREMAVSRLRDCLDRQALE 
MDP AAACTGGCGAAACTGGCGAAAAAACTGGCGAAACTGGCGAAA 
 
MDP KLAKLAKKLAKLAK 
ompF-yopM75-MDP ATGATGAAGCGCAATATTCTGGCAGTGATCGTCCCTGCTCTGTTA
GTAGCAGGTACTGCAAACGCTATGTTTATAACTCCAAGAAATGTA
TCTAATACTTTTTTGCAAGAACCATTACGTCATTCTTCTGATTTAA
CTGAGATGCCGGTTGAAGCAGAAAATGTTAAATCTAAGACTGAAT
ATTATAATGCATGGGCGGTATGGGAACGAAATGCCCCTCCGGGG
AATGGTGAACAGAGGGAAATGGCGGTTTCAAGGTTACGCGATTG
CCTGGACCGACAAGCCAAACTGGCGAAACTGGCGAAAAAACTGG
87 
 
 
 
CGAAACTGGCGAAA 
OmpF-YopM75-MDP MMKRNILAVIVPALLVAGTANAMFITPRNVSNTFLQEPLRHSSDLTE
MPVEAENVKSKTEYYNAWAVWERNAPPGNGEQR 
EMAVSRLRDCLDRQAKLAKLAKKLAKLAK 
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CHAPTER 4 
 
SIGNIFICANCE AND FUTURE DIRECTIONS 
 Engineering of CPP anticancer bio-agents 
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4.1. Significance of Research 
 The development of new anticancer agents with the ultimate goal of preventing 
and curing cancer has been the goal of researchers for many years. Current anticancer 
strategies employ a number of agents including natural products or peptide anticancer 
agents that target cancerous or pro-cancerous cell states.  Cancer drug targets include 
many distinct cancer pathways such as metabolic, apoptosis, genetic and epigenetic that 
distinguish individual cancer cell lines.   
 Many epigenetic targets have demonstrated their potential as a cancer therapy and 
continuing research in HDAC inhibition is focused on isoform-specific agents like 
FK228 that display better pharmacological properties that pan-HDAC inhibitors (1). 
Since the approval of FK228 by the FDA for cutaneous T-cell lymphoma more 
depsipeptide compounds like the thailandepsins and spiruchostatins have been identified 
with different HDAC selectivity and the potential to target different cancer types (2, 3).  
These depsipeptides share similar genetic organization and biosynthetic pathways and 
offer an opportunity for engineering hybrid depsipeptides with novel HDAC inhibitory 
function. 
 Further research of the FK228 biosynthetic pathway showed the in trans 
recruitment of both a Ppant transferase and an AT domain during the production of 
FK228.  The stand alone AT domain and Ppant transferase in C. violaceum were found to 
be constitutive genes suggesting that these proteins may be involved in essential cell 
functions.  The Sfp-type Ppant transferases found within the gene clusters are often 
dispensable for the associated polyketide or NRPS biosynthesis. However, our research 
suggests that Sfp-type Ppant transferases are essential to C. violaceum and the true 
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physiological role(s) for stand-alone Ppant transferase remains to be established.   
Previous research demonstrated and increased physiological role where the broad 
spectrum activity of  Sfp-type Ppant transferases substituted Ppant transfer activity for 
fatty acid biosynthesis in B. subtilis and Pseudomonas aeruginosa in the absence of 
ACPS-type Ppant transferases (4, 5).  
 The "stand alone" AT domain in C. violaceum demonstrated the first evidence of 
"cross talk" between modular NRPS-PKS systems and fatty acid biosynthesis pathways.  
The bridge between fatty acid biosynthesis and polyketide synthesis has been addressed 
previously in Streptomyces species containing many type II polyketide synthases which 
are analogous to the type II fatty acid biosynthetic pathway composed of discrete 
proteins.  Early findings showed S. coelicolor contained three different ACP-like 
proteins, rather than a single ACP, that were not shared among PKS and fatty acid 
biosynthesis pathways providing one level of pathway specificity (6).  Furthermore, 
FabD, the malonyl-CoA:AcpP acyl-transferase found in fatty acid biosynthesis was 
shown to be active on both AcpP and type II PKS ACPs (7).  FabD is often found within 
the fatty acid biosynthetic operon (E. coli) and a homologue from the fatty acid 
biosynthesis operon in S. glaucescens was shown to transfer malonate to both 
tetracenomycin (Tcm) ACP and fatty acid ACP. Alternatively,  pathway specificity may 
be determined by the carrier domains and the specific docking domain protein-protein 
interactions allow for the proper biosynthesis of fatty acid biosynthesis, PKS and NRPS 
pathways. Future research on the docking domains of ACPs will address questions 
associated with the similarity to fatty acid ACPs to elucidate the specificity and 
additional functions of these domains.  The expanded physiological roles of Ppant 
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transferases and acyl transferases suggests that they may represent new targets for 
antimicrobial treatment of bacteria that have these enzymes associated with essential 
pathways like fatty acid biosynthesis. 
 The future of CPP research will continue to develop new applications further 
enhancing the broad range of CPP activities.  Our research shows the engineering 
potential of CPPs for the development of new therapeutic agents.  However, in the future 
we would expand this project to engineer and express CPPs and CPP-fusion peptides in 
E. coli that can target specific cells, differentiate healthy from unhealthy cells and interact 
with specific intracellular pathways.  This new method for releasing the outer cell wall 
through L form bacteria production allowed CPP-MDP secretion to the media for rapid 
purification and may be expanded to purify new CPP-fusion constructs to test for 
anticancer activity.  The secretion of CDP-MDP into the media was critical for future 
research goals toward generating an anticancer CPP tumor targeting bio-agent.  Future 
experiments may require the development of a stable L form bacteria through genetic 
mutation(s) to prevent reversion back to the parental phenotype in the construction of 
these new CPP based bio-agents.  Also, the expression of the CPP may need to be 
adapted to the tumor microenvironment depending on the final host selected for growth 
and  CPP expression within the tumor. 
  
4.2. Targeting the tumor microenvironment 
 Cancer is a major public health problem facing mankind and yet the development 
of effective cancer treatments with no or few side effects remains one of the most 
difficult scientific challenges of our time. Cancer occurs in many types (such as breast 
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cancer, skin cancer, or leukemia – cancer heterogeneity) and the effectiveness of 
conventional treatments (surgical removal, radiotherapy and chemotherapy) varies (8). 
Consequently, there have been intensive efforts to develop alternative cancer therapies 
including bone marrow transplantation, immunotherapy, gene therapy, hormone therapy, 
and inhibition of angiogenesis (formation of blood vessels) or specific protein targets 
(mostly kinases) in key signaling pathways, all with mixed success (9). A fundamental 
requirement for any cancer therapy is to differentially suppress the proliferation of cancer 
cells or selectively eliminate cancer cells, while minimizing toxicity toward normal cells 
to an acceptable level.  
 Most human cancers are solid tumors. Solid tumors generally have an architecture 
in which the inner core maintains a very low oxygen microenvironment (known as 
“hypoxia”). Hypoxia occurs when tumor mass outgrows angiogenesis 10, 11). The 
hypoxic microenvironment of solid tumors often contains areas of necrosis that are 
resistant to both radiotherapy and chemotherapy; resistance to chemotherapy is, in part, 
due to the poor drug bioavailability as a result of the distance between inner tumor mass 
and peripheral blood vessels. Solid tumors with a hypoxic/necrotic core are also 
predisposed to increased tumor spreading (known as “metastasis”) (12). Paradoxically, 
the pathophysiologic characteristics of hypoxia in solid tumors also provide a unique 
opportunity for the development of tumor-selective treatments, including prodrugs 
activated by hypoxia, hypoxia-specific gene therapy, targeting the hypoxia-inducible 
transcription factor, and also the use of anaerobic bacteria as tumorcidal bio-agents (12).  
The early observations of cancer regression following bacterial infections in patients has 
inspired active pursuits of nonpathogenic anaerobic bacteria as anticancer bio-agents over 
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the last 60 years (13-15). In fact, the human body between external skin and inner 
digestive lumen is normally well oxygenated except for the hypoxic/necrotic cores within 
solid tumors where some anaerobic bacteria administered systemically through the blood 
circulation, or injected locally into solid tumors, can infiltrate and proliferate. As a 
consequence, tumor mass in the bacteria-colonized regions is selectively destroyed 
(known as “oncolysis”) and nutrients released are consumed by the bacterial population. 
The first generation of anticancer bio-agents were natural isolates of facultative or 
obligate anaerobic bacteria, belonging to the genus of Bifidobacterium, Clostridium, or 
Salmonella. Experiments performed on animal models or cancer patients demonstrated 
that administered bacterial spores or vegetative cells germinate and/or multiply in the 
hypoxic/necrotic regions of solid tumors, and that therefore limited oncolysis in these 
tumor regions can occur. However, a common problem hindering this approach is that 
anaerobic bacteria die when they reach to the outer layers of solid tumors where oxygen 
levels elevate. Some bacterial strains also produced endotoxins that resulted in excessive 
cytotoxicity toward normal cells, which inspired the creation of attenuated strains with 
proven safety records (16-18). Thus, the first generation of anticancer bio-agents could 
only destroy the inner parts of solid tumors but could not completely eradicate them; 
tumors would re-grow from the remaining viable outer rings. 
The second generation of anticancer bio-agents were genetically engineered anaerobic 
bacteria that produce prodrug-activating enzymes or tumor necrosis factors (13, 19). 
Prodrugs are injected intravenously and are activated by the enzymes at the sites of 
bacterial spore germination and vegetative growth inside solid tumors. This generation of 
anticancer bio-agents achieved greater oncolytic effects and some of them have actually 
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entered clinical trials, but the results have still not been sufficient to warrant practical 
cancer therapy. The effectiveness of prodrug injections is hampered by poor prodrug 
bioavailability due to the distance between peripheral blood vessels and the hypoxic core; 
an extra dose of tumor necrosis factor only slightly enhanced the necrosis in the already 
necrotic regions of solid tumors. Further improvement by combining anticancer bio-
agents with vascular-targeting chemicals resulted in still only modest increases of 
oncolytic activity (19). Nevertheless, the benefits of exploiting tumor hypoxia for cancer 
therapy have yet to be fully realized (12). 
 
4.3. Selection of anaerobic expression host 
 The production and secretion of CPPs will generate a new anticancer treatment 
combining the tumor targeting and anticancer activities of the bacteria with the anticancer 
activity of the CPPs.  The continuing  anticancer CPPs development in  E. coli 
BL21(DE3) can lead to the engineering of many specific anticancer agents that are 
capable of targeting multiple pathways to treat cancer.  E. coli BL21(DE3) can be used to 
engineer the anaerobic expression cassette, the integration of the expression into bacterial 
chromosome and CPP secretion into the media.  E. coli BL21(DE3) has been used 
successfully to express and secrete the CPP fusion proteins into the media. A secondary 
benefit of engineering E. coli strains is the potential for large scale media production of 
CPPs, because most current CPPs are chemically synthesized or derived from peptide 
digestion.   The expression cassettes constructed in E. coli strains can be easily modified 
by exchanging promoters and signal sequences targeting protein secretion pathways that 
work in different recipient anaerobic bacterial hosts such as Bifidobacterium longum and 
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attenuated Salmonella typhimurium. Both B. longum and S. typhimurium have higher 
(G+C) contents than that (50.8%) of E. coli, therefore codon usage would be evaluated 
and adjusted to accommodate these differences. Although B. longum and attenuated S. 
typhimurium have some shortcomings (Table 10), currently they are the best practical 
hosts for this research.  Clostridium novyi-NT and Clostridium sporogenes are Gram-
positive, spore-forming, strictly obligate anaerobic bacteria and have demonstrated strong 
oncolytic effects with a high degree of safety.  Although they would be adaptable hosts 
for the purpose, they are recalcitrant to genetic manipulation making them more difficult 
to use for this research (20). Transfer of the anaerobic expression cassette and integration 
into the genome of Clostridia strains represents a formidable task and may require new 
methods for efficient genetic transformation.  Also, since CPPs have shown greater 
antibacterial activity toward some Gram-positive bacteria than Gram-negative, both 
Clostridiaand Bifidobacterium may present additional challenges to CPP secretion 
system engineering (21,22).  Therefore, strains of Clostridia and Bifidobacterium are 
considered as secondary candidates for this research. 
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Table 10.. Parts of data were adopted from (13-15); E. coli strains are chosen as priming hosts for pilot experiments. 
Genus/Species
a
 Available?
b
 Genetically Engineerable?
c
 
(Comment/Reference) 
(G+C) 
Content
d
 
          Advantages
e
           Disadvantages
e
 Priority
f
 
E. coli BL21(DE3) 
or variant strains 
Commercial 
sources 
Yes (Genetic workhorse) (21) 50.8 - Easy genetics 
- Collateral benefit 
- Good for pilot experiments 
- Alone not strong oncolytic 
- Non-spore former 
 
Pilot/1st 
B. adolescentis - Yes (22) 59.2 - Non-toxic 
- Intravenous or oral 
administration 
- Modestly high (G+C)% 
content 
- Alone not strong oncolytic 
- Non-spore former 
- Difficult to store and handle 
- Susceptible to non-permissive 
conditions 
 
B. bifidum - Unknown (22)   
B. infantis - Yes (22) ~59-61  
B. longum Private, 
Public 
Yes (23,24) 60.1 1st 
C. acetobutyricum 
(C. beijerinckii) 
- Yes (25) 30.9 - Spore former 
- Spores are easy to produce, 
stable and economical to use 
- Intravenous administration 
- Demonstrated strong 
oncolytic ability 
- Demonstrated safety of 
nonpathogenic strains 
- Attenuated strains available 
- Some strains are pathogenic 
- Strain variation exists 
- Very low (G+C)% content 
- Difficult genetics 
 
C. novyi-NT and 
derived strains 
(attenuated) 
Private No  (16,20) 28.9 2nd 
C. sordellii - Unknown (16) ~28-30  
C. sporogenes 
(C. butyricum) 
(C. oncolyticum) 
Private, 
Public 
Yes but very difficult (26, 27) ~28-30 2nd 
S. choleraesuis - Yes (28) 52.1 - Intrinsic antitumor activity 
- Can target both large and 
small tumors 
- Attenuated strains available 
- Wild-type strains are 
pathogenic 
- Safety is a concern 
- May induce weak innate 
immune response 
- Alone not strong oncolytic 
 
S. typhimurium 
 VNP20009 
(attenuated) 
Private, 
Public 
Yes (29, 30) 52.2 1st 
a E. coli, Escherichia coli – Gram-negative, facultative, suitable for pilot experiments; B, Bifidobacterium – Gram-positive, obligate anaerobe; C, Clostridium - Gram-positive, strictly obligate anaerobe; 
S, Salmonella - Gram-negative, facultative anaerobe. Several strains of C. acetobutyricum were renamed as C. beijerinckii. Several strains of C. oncolyticum used to be named C. butyricum, and later 
renamed as C. sporogenes. 
b Private, private sources through (intended) collaborations; Public, public sources such as strain stock centers; -, not concerned. 
c Genetic engineerability refers to the availability of appropriate vectors and proven methods of bacterial transformation. 
d The (G+C) contents, wherever available, are from microbial genome databases. ~, Estimated. A close (G+C) content assumes similar codon usages.  
e Advantages/disadvantages collectively refer to the genus. 
f Subject to personal judgment. 
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Figure 18.  Anticancer bio-agent experimental design image.  A) Engineering of 
anticancer tumor targeting bacterium shows induction of gene expression in an anaerobic 
environment leading to secretion of anticancer cell penetrating peptide (CPP) and 
production of a reporter protein (Gfp).  B) The expression cassette module is activated 
under hypoxic condition leading to gene expression of CPP and reporter genes.  C) 
Production and formulation of bacterial spores or bacteria for testing in mouse cancer 
model.  D)  Future systemic application of tumor targeting CPP expressing anticancer 
bio-agents. Part D was adapted with permission from (31). 
 
4.4. CPP fusion peptide expression cassette design 
 Efficient production of CPPs in engineered bacteria requires all the necessary 
genes to be arranged properly under the proper regulatory circuits. Specifically, designing 
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the expression cassette with four exchangeable modules will allow rapid amendments to 
each individual component of the CPP expression system.  The first module will contain 
an interchangeable promoter from the given host genome so that the expression of the 
CPP gene is controlled by environmental influences simulating a hypoxic tumor 
microenvironment (Fig. 18B).  Since the genome sequences of all prioritized host 
bacteria but C. sporogenes are available, promoters activated under hypoxic growth 
conditions can be identified and verified experimentally. The second module will contain 
a signal sequence that directs the peptide to the corresponding protein secretion pathway. 
The third module will contain the CPP with transmembrane activity that can carry an 
anticancer protein or protein domain such as MDP, directed toward apoptosis or cancer 
pathways (Fig. 18A).  Some additional CPPs that possess inherent domain targeting 
ability that have anticancer activity could be used to increase the number of anticancer 
peptides expressed by the host (Table 10).  The CPPs may be modified to contain a small 
peptide or protein fusion product with known function to block protein/protein 
interactions and inhibit cell proliferation or induce apoptosis. The fourth module allows 
for co-expression of a fusion protein, another CPP, or a fluorescent marker gene (gfp) 
from the same promoter.  However, the fourth module may be optional.  In order to 
facilitate expression cassette transfer, integration and mutant selection in a receiving host, 
a marker gene (conferring antibiotic resistance) driven by a constitutive promoter would 
be placed upstream of the expression cassette.  Finally, the integration of the expression 
cassette into the host genome will be facilitated by transposon insertion to complete the 
construction of the anticancer CPP expressing bio-agent (Fig. 18C, Fig. 18D).   
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Table 10.  Cell penetrating peptides that display promising anticancer activity. 
 
CPP 
 
Protein Source Types of Cancer Mode of Action 
Bactericidal 
activity 
PNC-27
1
  
 
Hdm-2 binding 
protein 
Breast, colon, 
osteosarcoma 
Necrosis and p53 
binding apoptosis 
(32) 
Unknown 
PNC-28
1
  Hdm-2 binding 
protein 
Breast, colon, 
bone, pancreatic 
Apoptosis via p53 
(33) 
 
Unknown 
CytC
77-101
  
 
Cytochrome C Untested Apoptosis pathway 
via mitochondria 
(34) 
Gram + > Gram- 
PEGA-pVEG 
 
Vascular homing 
peptide 
Breast Anti-angiogenesis 
(35) 
Gram + > Gram- 
CB1a  
 
cecropins Stomach, lung, 
leaukemia 
Membrane 
disruption (36) 
Poor activity 
MAP
2
  
 
Artificial model 
amphipathic peptide 
Breast, leukemia, 
melanoma 
Membrane 
disruption (37) 
Gram + > Gram- 
Transportin
2
   
 
Galanin and 
mastoparan fragments 
Breast, leukemia, 
melanoma 
Membrane 
disruption (37) 
Gram + > Gram- 
1
PNC-27 and PNC-28 were synthesized with penetratin CPP attached to carboxyl terminus of Hdm-2 
binding protein that binds p53 
2
Map and Transportin show hemolytic toxicity 
 
 
 
4.5. Anti-tumor activity analysis in mouse tumor models 
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 Formulated anticancer bio-agents will be tested first on mouse models carrying 
human tumor xenografts by intravenous (systematic) injection (38-40). Anaerobic 
bacteria have demonstrated the ability to circulate safely through bloodstream, infiltrate 
and selectively (germinate if spores) grow inside solid tumors in the hypoxic/necrotic 
regions. As a pure physiological consequence, tumor mass will be destroyed and the 
released nutrients will be consumed by proliferating bacteria. Secondly, the bacterial 
growth under hypoxic conditions will activate gene expression from the anaerobic 
promoter and the anticancer cell penetrating peptide will be secreted outside of the cell.  
There is no need for injection of other anticancer prodrugs as anticancer CPPs are 
produced de novo inside solid tumors. Although obligate and facultative anaerobic 
bacteria will cease to grow and eventually die as they progress to the outer rings of solid 
tumors where the oxygen levels elevate or evoke an immune response, CPPs will 
continue to diffuse and selectively kill proliferating cancer cells. Therefore, a strong 
synergy between the physical consumption of cancer mass by engineered anaerobic 
bacteria and the anticancer activities of CPPs could have the potential to eradicate many 
kinds of solid tumors regardless of cancer genotype.  Promising test results on mouse 
models would warrant future tests on large animal models and cancer patients according 
to preclinical and clinical trials. 
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